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Summary 
 
GPR55 is a putative novel cannabinoid receptor that is capable of being activated by a subset of 
cannabinoid ligands and the endogenous lipid, L-α-lysophosphatidylinositol (LPI). GPR55 mRNA 
is expressed widely throughout the body, particularly in the brain, bone and immune tissue, and is 
also expressed at high levels in certain types of tumour. Understanding the physiological and 
pathological role of GPR55 has been challenging due to the absence of selective pharmacological 
tools. However, novel antagonists have recently been developed, allowing for the determination 
of GPR55-selective effects. The objective of the present study was to utilise molecular imaging 
techniques to evaluate the effectiveness of two previously published novel GPR55 antagonists on 
LPI-mediated GPR55 responses, in a  HEK293 cell line stably expressing GPR55 (hGPR55-
HEK293) and also in a prostate cancer cell line that expresses GPR55 endogenously at high levels 
(DU145). Antagonist effectiveness was also examined in a neuronal model of Alzheimer’s disease 
(AD). The effects of the antagonists on LPI-mediated calcium (Ca2+) responses and cAMP-
response element-binding protein (CREB) phosphorylation were evaluated. In hGPR55-HEK293 
cells, treatment with antagonists at varying concentrations did not have an effect on intracellular 
Ca2+ levels or alter CREB phosphorylation when applied alone. However, both inhibited increases 
in Ca2+ signal induced by GPR55 agonists when applied at 3 µM. Overall, this data suggests that 
the GPR55 antagonists are active in in vitro models that over-express GPR55. Such 
pharmacological tools will help to advance the research on the physiological function of GPR55.  
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Chapter One 
 
Introduction 
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1.1. Cannabinoid signalling 
 
The hemp plant Cannabis sativa was thought to originate from Central Asia thousands of years ago 
and has since been associated with many uses, with one of the most well-known being recreational 
consumption (Iversen, 2000; Leonard, 2003). Cannabinoids occur naturally in Cannabis sativa and 
were originally described as a family of oxygen-containing 21-carbon aromatic hydrocarbon 
compounds. The principal psychoactive constituent of the plant is Δ9-tetrahydrocannabinol (Δ9-
THC), which was first isolated by Gaoni and Mechoulam in 1964. However, cannabinoids no 
longer encompass compounds that are derived solely from the hemp plant. The term now refers 
to substances that are capable of either mimicking the pharmacological effects of plant-derived 
cannabinoids, or have similar chemical structures to plant-derived cannabinoids. As a result, 
cannabinoids that are expressed endogenously are referred to as “endocannabinoids” whereas 
naturally occurring cannabinoids sourced from the cannabis plant, such as Δ9-THC and 
cannabidiol (CBD), are now referred to as “phytocannabinoids” (Irving et al., 2002; Pertwee, 2005, 
2010). There are also “synthetic cannabinoid” compounds (Iversen, 2000).  
 
Cannabinoids exert their primary effects through cannabinoid receptors (Pacher & Kunos, 2013). 
To date, two types of endogenously expressed cannabinoid receptor have been identified. CB1 
receptor was first cloned in 1990 by Matsuda et al. and CB2 receptor by Munro et al. in 1993. The 
two principal endocannabinoids that interact with these receptors are anandamide (N-
arachidonylethanolamine; AEA) and 2-arachidonylglycerol (2-AG). AEA and Δ9-THC bind with 
higher affinity to CB1, whereas 2-AG binds primarily to CB2 (Pacher & Kunos, 2013; Pertwee et al. 
2010). Both receptors belong to the family of G protein-coupled receptors (GPCR). Upon ligand 
binding, both of these receptors mediate a signalling system that results in the inhibition of 
adneylate cyclase and the activation of mitogen-activated protein kinase (MAPK) through Gαi/o 
protein coupling. Inhibitory effects of G protein beta-gamma (βγ) subunits on voltage-gated Ca
2+ 
channels have also been reported following CB1 receptor activation (Guo & Ikeda, 2004). 
However, CB1 receptors have also been reported to couple to stimulatory Gαs proteins (Pertwee 
et al., 2010).  
 
CB1 receptors are abundantly expressed in the brain, whereas CB2  receptors are expressed at high 
levels peripherally (e.g. on immune cells) with lower levels found in the CNS. For this reason CB1 
receptors are thought to mediate the main psychoactive effects of cannabis. CB1 receptors are 
expressed by central and peripheral neurons, along with some non-neuronal cells such as microglia 
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(Cabral & Marciano-Cabral, 2005; Pertwee, 2005). Recent evidence has suggested that CB1 
receptor expression can also occur peripherally in almost all tissues and cell types (Di Marzo, 2008; 
Pacher & Mechoulam, 2011; Pacher et al. 2006). It has been suggested that CB2 receptors can also 
be expressed by some types of neurons (Rodríguez-Cueto et al., 2013; Ross et al., 2001; Van Sickle 
et al., 2005), as well as being found on CNS-resident immune cells (e.g. microglia; Pertwee, 2005). 
 
Despite the apparent abundance with which cannabinoid receptors are expressed in various tissues 
and cell types, there is evidence that these receptors are not the only ones responsible for mediating 
the physiological effects of cannabinoid ligands. Studies conducted with CB1
-/- and CB2
-/- mice have 
aided in the identification of additional cannabinoid-sensitive targets (Mackie & Stella, 2006). It is 
now believed that certain orphan receptors which couple to heterotrimeric guanine nucleotide-
binding proteins (G-proteins) are capable of responding to cannabinoid ligands. One such example 
is the orphan G-protein coupled receptor, GPR55.  
 
1.2. The structure of GPR55 
 
GPR55 was first identified by Sawzdargo et al. (1999) using cloning experiments and was found to 
be expressed at high levels in the human striatum. Its structural characteristics were found to be 
consistent with other GPCRs, including its possession of seven hydrophobic regions 
corresponding to seven putative transmembrane regions; conserved first and second extracellular 
loop cysteines; and a DRY motif in the N-terminal part of the second intracellular loop (Sawzdargo 
et al., 1999). It has been categorised into the Class A or Rhodopsin-like family of seven-
transmembrane spanning GPCRs (Henstridge et al., 2011; Müller et al., 2012).  The GPR55 gene is 
located on chromosome 2 in mice and chromosome 6 in humans and its open reading frame was 
found to encode a short protein comprised of 319 amino acids (Sawzdargo et al., 1999). GPR55 
shares sequence homology with purinergic receptor P2Y5 (29%), the purinergic receptor-like 
orphan receptors GPR23 (30%) and GPR35 (27%), the chemokine receptor CCR4 (23%) and with 
the lysophosphatidic acid (LPA) receptor GPR92/LPA5 (Ryberg et al., 2007; Sawzdargo et al., 1999; 
Yin et al., 2009). Interestingly, GPR55 has much less homology with the classical cannabinoid 
receptors, CB1 (13.5%) and CB2 (14.4%) (Henstridge et al., 2011; Sharir & Abood, 2010). This 
discrepancy has led to speculation over whether it is a good candidate for being a putative novel 
cannabinoid receptor. 
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1.3. Ligand-biased signalling 
The activation of GPCRs by ligands leads to alterations in receptor conformation. The signal 
transduced from these ligand-receptor interactions can in turn lead to the activation of G-proteins. 
G-proteins consist of Gα and Gβγ subunits. Several types of Gα subunits exist, including Gαs, 
Gαi, Gαq/11 and Gα12/13 (Hurowitz et al., 2000). G-proteins function as molecular switches. Their 
activation on the inner surface of the cell membrane by a transmembrane-spanning GPCR causes 
the Gα subunit to dissociate from the Gβγ subunit and to exchange guanine diphosphate (GDP) 
for guanine triphosphate (GTP). The activated G-protein then induces a signalling cascade 
downstream (Hurowitz et al., 2000). Ligands are capable of inducing GPCRs to selectively 
transduce their signals via distinct G-proteins to a certain mediator/second messenger over 
another, leading to specific cellular responses and effects depending on the efficacy of the ligand 
for the receptor (Khoury et al., 2014). GPCRs can adopt multiple conformations e.g. active and 
inactive states, and ligands can stabilise these receptor conformations by inducing the “on” 
conformation with respect to one signalling pathway and the “off” conformation for another 
pathway. This differential-signalling concept is known as biased agonism or ligand-biased signalling 
(Onaran, Rajagopal, & Costa, 2014) and the ability of a ligand to induce certain signalling effects 
has led to the classification of ligands into agonists, antagonists and inverse agonists (Khoury et al., 
2014). GPR55 stimulation leads to signal transduction involving the activation of various effectors, 
and therefore has the potential for agonist-biased signalling. 
 
1.4. Ligand-induced GPR55 signalling 
 
Ligand binding to GPR55 induces a signalling cascade that leads to various cellular effects (Sharir 
& Abood, 2010). Although it is now widely accepted that GPR55 transduces signals via a G-protein 
coupled mechanism, there is still speculation over which type of heterotrimeric G-protein this 
receptor couples to. Initial experiments using specific peptides to block Gαs and Gαi proteins, as 
well as inhibitors of each G-protein subtype, were conducted in order to determine which G-
protein coupled to GPR55. This led to the characterisation of Gα13 as a potential mediator of 
GPR55 signalling (Ryberg et al., 2007). Other studies such as the one conducted by Lauckner et al. 
(2008) suggested that GPR55 coupled to Gα12 and Gαq proteins. Some reports even suggest that 
different signalling arms could be activated by the same GPR55 ligand, with stimulation of both 
10 
 
Gα13 and  Gαq signalling pathways occurring after ligand-induced GPR55 activation in sensory 
neurons (Gangadharan et al., 2013).  
In support of the findings reported by Ryberg et al. (2007) though, an extensive study performed 
by Henstridge et al. (2009a) using the human embryonic kidney cell line, hGPR55-HEK293, 
implicated a Gα13-RhoA-Rho-associated protein kinase (ROCK) signalling cascade to be 
associated with GPR55. This cascade induces phospholipase-C-ε (PLCε) activation, which leads 
to inositol 1,4,5-triphosphate (IP3) formation followed by the release of Ca
2+ from internal 
endoplasmic reticulum (ER) stores (Figure 1). This Ca2+ increase was shown to trigger the 
activation of nuclear factor of activated T-cells (NFAT) proteins. Once activated, NFAT 
translocates to the nucleus and causes gene transcription. It has also been suggested that there are 
other downstream effectors of GPR55 activated by the Gα13-RhoA-ROCK cascade, including 
ERK, protein kinase B/Akt, p38 MAPK and activating transcription factor-2 (ATF-2) (Oka et al., 
2010; Piñeiro et al., 2011). The functionality of these effectors appears to differ from cell type to 
cell type (Gasperi et al., 2013). It has previously been found that Gαq is required for LPI-induced 
Ca2+release from intracellular stores in DU145 prostate cancer cells (Penman, 2013) via PLCβ-
mediated hydrolysis of PIP2 into IP3 and DAG (Hubbard & Hepler, 2006). IP3 then goes on to 
induce the release of Ca2+ from intracellular ER stores (Clapham, 2007). In Figure 1, Gα13-coupled 
signalling as determined in HEK293 cells stably overexpressing hGPR55 (Fig 1. (A)), and Gαq-
coupled signalling in the DU145 prostate cancer cell line (Fig 1. (B)) is illustrated. 
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Agonist stimulation of GPR55 and subsequent signalling also induces receptor trafficking. GPR55 
normally resides on the cell membrane but agonist stimulation leads to its internalisation. Methods 
used to observe this internalisation include the use of haemagglutinin (HA) antibodies, which bind 
to GPR55 tagged with the HA epitope, and β-arrestin assays (Henstridge et al., 2009a, 2010; Sharir 
et al., 2012). β-arrestins can be recruited to activated GPCRs to form stable receptor-arrestin 
complexes that can be monitored following agonist stimulation using β-arrestin detector assays 
(Kapur et al., 2009; Yin et al., 2009). 
 
1.5. Phosphorylation of cyclic AMP (cAMP)-response element binding protein (CREB) 
cAMP-response element binding protein (CREB) is a transcription factor that is widely expressed 
in the body, with particularly high levels of expression found in the brain (Carlezon Jr et al., 2005). 
It was initially found that cAMP induced the transcription of somatostatin gene via the 
phosphorylation of CREB at Serine 133 (Gonzalez & Montminy, 1989). CREB phosphorylation 
occurs via different effectors depending on cell type, with some mediators including protein kinase 
A (PKA), Ca2+-calmodulin-dependent protein kinases (CaM kinases), MAPKs (Carlezon Jr et al., 
2005; Gonzalez & Montminy, 1989; Sheng et al., 1991), PKC (Johannessen et al., 2004) and more. 
Phosphorylation of CREB leads to the translocation of phospho-CREB (pCREB) to the cell 
(A) 
(A) 
Figure 1. GPR55 signalling cascade following agonist stimulation and coupling to Gα13 
protein in hGPR55-HEK293 cells and Gαq in DU145 prostate cancer cells. (A) Upon activation 
of GPR55, Gα13 protein couples to GPR55 and stimulates RhoA GTPase activity. RhoA then 
activates Rho kinase (ROCK) which in turn induces PLCε to hydrolyse PIP2 to IP3 and DAG. IP3 
causes the release of Ca2+ from intracellular stores. This increase in cytoplasmic Ca2+ levels leads to 
the activation and translocation of NFAT to the cell nucleus. Once in the cell nucleus, NFAT induces 
transcription of DNA and gene expression. Cytoplasmic calcium has also been reported to lead to 
the stimulation of ERK. ERK and other kinases such as JNK and p38 MAPK all go on to induce 
gene transcription by activating transcription factors within the cell nucleus. (B) Upon activation of 
GPR55, Gαq protein couples to GPR55 and stimulates PLCβ which hydrolyses PIP2 to IP3 and DAG. 
DAG activates PKC. IP3 causes the release of Ca2+ from intracellular stores. Effectors such as ERK 
stimulate transcription factors in the nucleus to induce gene expression. This gene expression leads 
to metastasis of cancer cells. Ca2+ is suggested to induce cell metastasis as well. DAG: diacylglycerol; 
GTP: guanosine triphosphate; PIP2: phosphatidylinositol 4,5-bisphosphate; JNK: c-Jun N-terminal 
kinases; PKC: Protein Kinase C.  
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nucleus and the activation of CREB-mediated gene transcription (Stevenson et al., 2001). Some 
examples of expressed genes include c-Fos, cAMP response element modulator (CREM) and brain-
derived neurotrophic factor (BDNF) (Carlezon Jr et al., 2005). Due to its high levels of expression 
within the brain, CREB is believed to play an important role in synaptic plasticity, memory 
consolidation and learning (Carlezon Jr et al., 2005; Josselyn & Nguyen, 2005). CREB is also 
suggested to function in glucose homeostasis, growth-factor-dependent survival (Mayr & 
Montminy, 2001), in the control of uterine activity  during pregnancy (Bailey, 2000) and in 
spermatogenesis (Walker & Habener, 1996).  
Numerous receptors on the cell membrane are suggested to mediate intracellular signalling 
pathways that ultimately lead to CREB activation within the cell nucleus. Some examples of these 
receptors include neurotrophin receptors e.g. TrkB, N-methyl-D-aspartate (NMDA) receptors and 
GPCRs (Carlezon Jr et al., 2005). Upon ligand stimulation, GPR55 mediates the downstream 
activation of various transcription factors, including CREB phosphorylation (Henstridge et al., 
2010). 
 
1.6. GPR55 pharmacology: agonism 
 
Despite the vast amount of research carried out surrounding the pharmacology of GPR55, the 
issue of whether or not it is a true cannabinoid receptor has not been resolved. Numerous reports 
have provided evidence that GPR55 is sensitive to cannabinoid ligands, thus supporting this 
notion. Indeed, Ryberg et al. (2007) reported that HEK293 cells stably transfected with hGPR55 
were activated by nanomolar (nM) concentrations of various endocannabinoids, including AEA, 
2-AG. This study also reported that the phytocannabinoid Δ9-THC and synthetic cannabinoids 
e.g. O-1602, the inverse CB1 agonist AM251, activated downstream signalling mechanisms via 
GPR55. These signalling mechanisms led to GTPγS binding. However, other studies only 
reproduced some of the results shown by Ryberg et al. (2007) in the hGPR55-HEK293 cell line 
(Johns et al., 2007), while another research group could not reproduce any of the findings (Oka et 
al., 2007).  
In contrast, there are reports suggesting that endocannabinoids are not the most potent class of 
endogenous agonists of GPR55. Various studies have found that a different class of endogenous 
lyso-phospholipid interacts more effectively with GPR55. L-α-lysophosphatidylinositol (LPI) has 
previously been suggested to be the endogenous ligand for GPR55 (Nevalainen & Irving, 2010; 
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Piñeiro & Falasca, 2012), with the 2-arachidonyl species of LPI being the most potent based on 
structure-activity relationships (Oka et al., 2009). LPI has been reported to activate other orphan 
GPCRs. For instance, it was found that LPI significantly induced intracellular cAMP accumulation 
via the orphan GPCR, GPR119, in a dose-dependent manner in rat hepatoma cells stably 
expressing human GPR119 (Soga et al., 2005). However, Piñeiro et al. (2011) found that 
knockdown of GPR119 had no effect on LPI-induced ERK activation and the release of Ca2+ 
from stores in prostate and ovarian cancer cell lines, which indicates that GPR55 was mediating 
those effects. Other suggested lipid agonists at GPR55 include N-arachidonoyl-serine (ARA-S) 
(Zhang et al., 2010) and palmitoylethanolamide (PEA) (Mackie & Stella, 2006).  
Studies conducted in order to produce next-generation agonists for GPR55 have attempted to 
model those agonists on LPI because LPI has been found to possess a conformation and binding 
mode that is suitable for interaction with GPR55 (Kotsikorou et al., 2011a, 2011b). LPI-mediated 
stimulation of GPR55 leads to the activation of downstream signalling cascades that are consistent 
with what is already known about the pharmacological effects associated with GPR55 activation. 
Some examples of these effects include GPR55 receptor internalisation, Ca2+ release, NFAT 
activation, ERK phosphorylation and p38 MAPK activation (Henstridge et al., 2009a; Oka et al., 
2007, 2010). 
Although LPI is currently the most potent endogenous GPR55 agonist, ligand selectivity for 
GPR55 has recently come under scrutiny. For instance, the synthetic GPR55 agonist O-1602 also 
activates the orphan receptor GPR18 (Ashton, 2012). Recent findings suggest that N-arachidonyl-
glycine (NAGly), the endogenous agonist for GPR18 (Kohno et al., 2006), also activates GPR55 
(Penman, 2013). Findings such as these have led to the suggestion that GPR55 communicates with 
GPR18, thereby altering ligand selectivity under certain physiological circumstances. This is why 
it is ever more pertinent to identify other potent and specific agonists for GPR55. Heynen-Genel 
et al. (2011) identified several potent and selective agonists for GPR55 – ML184 (2440433) with 
263 nM potency for GPR55; ML185 (CID1374043) with 658 nM potency for GPR55; and ML186 
(CID15945391) with 305 nM potency for GPR55. The agonists were all found to cause 
downstream ERK phosphorylation and PKC β II translocation. Brown et al. (2011) identified the 
benzoylpiperazines, GSK494581A and GSK575594A, as GPR55 agonists, which were originally 
patented as inhibitors of glycine transporter subtype 1 (GlyT1). GSK575594A was 60-fold 
selective for GPR55 (pEC50 = 6.8) over GlyT1 (pIC50 = 5.0). However, these agonists only showed 
activity at human GPR55, whereas endogenous agonists such as LPI show specificity for both 
human and rodent GPR55. It could be disadvantageous to use these agonists in studies that utilise 
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tissue and in vivo models if one wished to compare human and rodent orthologs of GPR55. 
Nevertheless, with the discrepancies surrounding the selectivity of cannabinoid ligands and LPI 
for GPR55, it is therefore important to continue identifying selective GPR55 agonists in order to 
truly characterise the physiological role of GPR55. 
 
1.7. GPR55 pharmacology: antagonism 
 
Although there appears to be no shortage of potential agonist ligands for GPR55, only a small 
number of putative antagonists have been identified. Some research groups have suggested that 
certain cannabinoid ligands act as GPR55 antagonists. The cannabinoid ligand CP55,940 was 
found to antagonise LPI-induced release of Ca2+ from ER stores in hGPR55-HEK293 cells 
(Henstridge et al., 2009a). Lauckner et al. (2008) reported that low micromolar (µM) concentrations 
of CB1 antagonist SR141716A (rimonabant) caused antagonism of GPR55 and a decline in Ca
2+  
when co-perfused with various agonists (Δ9-THC, methanandamide (MEA) and JWH015) in 
hGPR55-HEK293 cells and dorsal root ganglion (DRG) neurons. JWH015 and Δ9-THC did 
antagonise GPR55 and cause a reduction in Ca2+ release in DRG neurons when co-perfused with 
SR141716A but MEA did not. In contrast, Kapur et al. (2009) and Henstridge et al. (2009b, 2010) 
demonstrated that varying concentrations of SR141716A caused agonist-induced effects to occur 
via GPR55 stimulation in human osteosarcoma and hGPR55-HEK293 cells respectively. The 
differing effects of SR141716A previously reported may have been related to the doses used, 
efficacy and even cell type (Sharir & Abood, 2010). However, it is also worth noting that 
SR141716A is structurally similar to the CB1 inverse agonist AM251, which  has previously been 
reported to have agonistic effects at GPR55 (Henstridge et al., 2009b, 2010; Ryberg et al., 2007).  
 
Cannabidiol was suggested to act as a GPR55 antagonist in a GTPγS-binding assay (Ryberg et al., 
2007). Similarly, the cannabidiol analogue O-1918 has been identified to act as a GPR55 antagonist 
in several studies. Schmuhl et al. (2014) recently demonstrated that GPR55 antagonism with O-
1918 or CBD induced mesenchymal stem cell migration. This pro-migratory effect was associated 
with concentration-dependent activation of p42/44 MAPK, and was inhibited by pre-treating cells 
with the GPR55 agonist O-1602 (Schmuhl et al., 2014). O-1918 inhibited the firing of nociceptive 
C fibres induced by O-1602 in a rat model of acute joint inflammation (Schuelert & McDougall, 
2011). Interestingly, O-1918 is a recognised antagonist of GPR18. O-1918 inhibited the effects on 
intraocular pressure (IOP) induced by the GPR18 agonists Abnormal-CBD (Abn-CBD) and 
NAGly in a murine model (Caldwell et al., 2013). O-1918 inhibited the NAGly-, Abn-CBD-, and 
16 
 
O-1602-induced cellular migration of both BV-2 microglia and GPR18-HEK293 transfected cells 
(McHugh et al., 2010). O-1918 was suggested to equivalently antagonise the vasodilator effects of 
Abn-CBD in WT and GPR55-KO murine models (Johns et al., 2007), which could lead one to 
speculate that the observed antagonistic effects on vasodilation could instead have been GPR18-
mediated. O-1602 and NAGly have been identified as both GPR55 (Romero-Zerbo et al., 2011; 
Schuelert & McDougall, 2011; Penman, 2013) and GPR18 (Ashton, 2012; Kohno et al., 2006) 
agonists. Given that O-1918 is theorised to act as an antagonist at both GPR55 and GPR18, it 
seems more likely than ever that these receptors are capable of communicating with one another.  
 
Rempel et al. (2013) used β-arrestin assays to identify 3-substituted coumarins as GPR55 
antagonists. Structure-activity relationships were performed and compared to CB1, CB2 and GPR18 
receptors. The study showed that when there was no lipophilic residue in position 7 of the 
coumarin scaffold, this resulted in the antagonism of LPI-induced β-arrestin translocation. In 
contrast, these compounds had little or no affinity for CB receptors or GPR18. Coumarin 
derivatives with an enhanced alkyl moiety possessed the greatest antagonistic potency in the series 
of compounds tested. 7-(1,1-Dimethyloctyl)-5-hydroxy-3-(2-hydroxybenzyl)-2H-chromen-2-one 
(PSB-SB-487, IC50 = 0.113 μM, KB = 0.561 μM) and 7-(1,1-dimethylheptyl)-5-hydroxy-3-(2-
hydroxybenzyl)-2H-chromen-2-one (PSB-SB-1203, IC50 = 0.261 μM) were the two most potent 
GPR55 antagonists tested. Interestingly, these two compounds also acted as potent CB2 receptor 
agonists in this study. The compounds could therefore be useful therapeutic tools for the study of 
cross-talk mechanisms and dual functionality between CB2 and GPR55 in the future (Rempel et al., 
2013). 
 
Previous studies such as the ones described in this section have identified putative GPR55 
antagonists. However, these antagonists are not completely selective for GPR55 and this lack of 
selectivity considerably limits their suitability as pharmacological tools. This makes the need for 
pharmacologically specific or selective GPR55 antagonists all the more essential so that the 
(patho)physiological roles of GPR55 can be properly elucidated. A study conducted by Heynen-
genel et al. (2011) screened for selective GPR55 antagonists. Three potent antagonists were 
reported on in that study, one of which being the piperadinyloxadiazolone ML191 (3-[1-[1-(4-
methylphenyl)cyclopropanecarbonyl]piperidin-4-yl]-5-phenyl-1,3,4-oxadiazol-2-one), which is 
also referred to as D327-0013. D327-0013 was reported to have 160nM potency for GPR55 in a 
β-arrestin high-content screen (HCS) assay and was capable of inhibiting the downstream 
signalling responses of ERK phosphorylation and PKC translocation. Another antagonist was also 
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screened for during that study but the data was not published at the time. The antagonist in 
question, known as CID16020046 ((4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-oxo-
1H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-5-yl] benzoic acid) or C390-0219, was originally reported to 
antagonise GPR55-mediated β-arrestin internalisation (Abood, 2010). Kargl et al. (2013) recently 
performed a study and reported that C390-0219 antagonised agonist-induced receptor trafficking 
in yeast cells expressing hGPR55 and LPI-mediated effects in the hGPR55-HEK293 cell line e.g. 
LPI-induced Ca2+ release, stimulation of ERK, NFAT and Nuclear factor ĸ of activated B cells 
(NF-ĸB). Kargl et al. (2013) also showed that C390-0219 prevented LPI-induced stimulation of 
wound healing in human lung microvascular endothelial cells (HMVEC-L) (Kargl et al., 2013). The 
potency of C390-0219 at GPR55 and the inhibition of LPI-mediated effects was estimated to be 
between 0.1–1 µM in that study.  
 
The structures of both D327-0013 and C390-0219 are illustrated in Figure 2. Both antagonists 
were used in a study conducted by Kotsikorou et al. (2013) to characterise their structures and 
conformations. The antagonists possess a head region that occupies a horizontal binding pocket 
extending into the extracellular loop region of GPR55; they possess a central ligand segment that 
occupies a vertical binding region of GPR55; and they possess aromatic rings that extend out from 
their central regions and are located deepest in the horizontal binding pocket of GPR55. The study 
was carried out in order determine their functionality as GPR55 antagonists and also to facilitate 
the creation of more potent and effective next-generation antagonist ligands that are selective for 
GPR55. This will prove beneficial in future because the most effective GPR55 antagonist can be 
used to evaluate the therapeutic potential of GPR55.  
 
18 
 
 
 
 
1.8. The expression and (patho)physiological function of GPR55 
 
The GPR55 receptor is expressed in many different tissues and cell types. Numerous studies have 
provided evidence supporting GPR55 expression in the blood, cardiovasculature, bone 
metabolism (Henstridge et al., 2011), the brain (Sawzdargo et al., 1999), the gastrointestinal tract 
(Ryberg et al., 2007) and pancreatic tissue (Bondarenko et al., 2010, 2011), to name but a few.  
Due to its fairly ubiquitous expression, GPR55 has been implicated in numerous 
pathophysiological conditions e.g. neurological diseases, inflammatory and neuropathic pain, 
osteoporosis and diabetes (Henstridge et al., 2011). GPR55 has also been increasingly linked to 
having a regulatory role in cancer. Cannabinoid signalling via cannabinoid receptors has previously 
been shown to elicit anti-cancer effects and to regulate cancer cell proliferation in different in vitro 
and in vivo models of cancer (Alexander et al., 2009; Guzmán, 2003). Similarly, certain cannabinoids 
such as AM251, SR141716A and others, act as ligands at GPR55 (Henstridge et al., 2009b, 2010; 
Kapur et al., 2009; Ryberg et al., 2007), thus implicating GPR55 in having a potential role in the 
regulation of cancer cell activity. Indeed, studies have provided evidence that links GPR55 
stimulation to the promotion of cancer cell proliferation in various models of cancer. For instance, 
levels of the established GPR55 agonist LPI were found to be augmented in the plasma of female 
patients with ovarian cancer compared to healthy patients (Oka et al., 2007). LPI was shown to be 
D327-0013 [ML191]
(3-[1-[1-(4-
methylphenyl)cyclopropanecarbonyl
]piperidin-4-yl]-5-phenyl-1,3,4-
oxadiazol-2-one)
C390-0219
(4-[4-(3-hydroxyphenyl)-3-(4-
methylphenyl)-6-oxo-1H,4H,5H,6H-
pyrrolo[3,4-c]pyrazol-5-yl] benzoic 
acid) 
Figure 2. Chemical structures of GPR55 antagonists. Adapted from Heynen-
Genel et al. (2011) and Kotsikorou et al. (2013). 
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secreted by fibroblasts, epithelial cancer cells and transformed thyroid cells. This led to mitogenic 
effects and it was suggested that LPI was a mitogen that could play a role in Ras-dependent cell 
proliferation (Falasca & Corda, 1994; Falasca et al., 1995, 1998). Overexpression of GPR55 and 
LPI caused an increase in cell migration, cell viability and ERK activation in breast and glioma 
cancer cells (Andradas et al., 2011; Ford et al., 2010). ERK is an important mediator of cell 
proliferation because it regulates the activity of transcription factors e.g. c-Fos, c-Jun. These genes 
are well-known oncogenes and upon their dysregulation they aid in modulating the rates of cell 
proliferation in carcinogenesis (Formosa & Vassallo, 2014). Studies such as these suggest that 
GPR55 is a regulator of pro-cancer activity. However, the modulation of GPR55-mediated 
signalling pathways may have a therapeutic impact. Blockade of GPR55 using small interfering 
RNA (siRNA) decreased cellular proliferation in prostate and ovarian cancer cells (Andradas et al., 
2011; Piñeiro et al., 2011). The formation of GPR55-CB2 heteromers in human breast 
adenocarcinoma cells and in human glioblastoma cells was shown to have a major impact on 
cannabinoid signalling and pharmacology in these cells and it was suggested that the modulation 
of these receptors could potentiate anti-tumoural activity in vivo (Moreno et al., 2014). In 
consideration of this evidence, the use of GPR55 antagonists to inhibit GPR55 signalling could 
have therapeutic effects in models of cancer. 
 
1.9. GPR55 and apoptosis 
In contrast to the potential role GPR55 has in promoting cell proliferation, GPR55 has recently 
been linked to promoting programmed cell death in certain cell types and in different physiological 
conditions. Apoptosis is vital for the removal of unwanted and potentially harmful cells during 
developmental processes, homeostasis and disease (Jacobson et al., 1997; Thompson, 1995). 
Although there are various mediators that function in the apoptotic pathway, the cysteine-aspartic 
proteases or caspases are particularly essential. Caspases are an evolutionarily conserved family of 
proteases and 14 types have been identified in mammals to date (Zhang et al., 2003). Although 
largely linked with apoptosis and inflammation in the past, newer evidence now links caspases to 
having major roles in promoting cell survival, proliferation and differentiation (Lamkanfi et al., 
2007).  
There are two types of apoptotic pathway: extrinsic and intrinsic. In the intrinsic apoptotic 
pathway, various signals directly or indirectly alter mitochondrial membrane permeability which 
leads to the release of intermembrane proteins from the mitochondria e.g. cytochrome c, into the 
20 
 
cytoplasm. In the cytoplasm, cytochrome c assembles with procaspase-9 and apoptotic protease 
activating factor 1 (apaf-1) to form an apoptosome. Procaspase-9 is cleaved and activated in the 
apoptosome. Activated caspase-9 then goes on to cleave and activate other downstream caspases 
e.g. caspase-3 (Zhang et al., 2003). 
Caspase-3 is a frequently activated death protease, also known as an executioner caspase. It 
functions in apoptotic processes in a cell- and tissue-specific manner (Porter & Jänicke, 1999). In 
pathological conditions such as cancer, caspase-3 and apoptosis are downregulated. GPR55 can 
play a role in mediating this downregulation. Piñeiro et al. (2011) measured caspase-3 activity in 
cancer cells transfected with GPR55 siRNA which led to an absence of apoptosis induction. From 
these findings they suggested that GPR55 was critical for the regulation of cell proliferation.  
Caspases such as caspase-3 also have a major role in normal brain development and in the 
progression of neurological disorders. In chronic neurodegenerative disorders such as Alzheimer’s 
disease for instance, caspase-dependent apoptotic mechanisms promote cell dysfunction, synaptic 
failure and cognitive dysfunction (D’Amelio et al., 2011; Friedlander, 2003). In the brains of 
Alzheimer’s patients, a four-fold increase in caspase-cleaved amyloid precursor protein (APP) 
fragments was discovered in comparison to age-matched controls (Banwait et al., 2008; Bredesen, 
2009). Cannabinoids have a regulatory effect on processes such as these. Δ9-THC has previously 
been shown to induce apoptosis in cortical neurons via a caspase-3 dependent mechanism 
(Campbell, 2001; Downer et al., 2007; Gowran et al., 2011). Interestingly, GPR55 mRNA 
expression has been identified in different regions of the brain e.g. frontal cortex, hypothalamus, 
striatum, amygdala and cerebellar granule cells (Chiba et al., 2011; Kerr et al., 2013; Ryberg et al., 
2007; Sawzdargo et al., 1999) and in microglia (Pietr et al., 2009). It would now be of particular 
interest to examine whether GPR55 also has a regulatory role over caspase-3 and apoptotic 
mechanisms in primary neuronal cell models.  
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GPR55 is a putative cannabinoid receptor which responds to certain cannabinoid ligands along 
with other endogenous lipids. Its most potent endogenous ligand to date is believed to be LPI. 
However, an absence of selective GPR55 ligands up until recently has made it difficult to elucidate 
the physiological and pathological processes mediated by this receptor. This is particularly true of 
cells that express GPR55 endogenously, whereby there is greater potential for non-specific binding 
of ligands. Thus, the development of new GPR55-selective pharmacological tools will allow for a 
much greater understanding of the physiological and pathological roles of GPR55. 
 
OBJECTIVES 
The objectives of this research project were as follows: 
1. To compare GPR55-mediated responses in a stable cell line that stably expresses 
recombinant human GPR55 (hGPR55-HEK293 cells) with a prostate cancer cell line that 
expresses GPR55 endogenously at high levels (DU145). 
2. To determine the effectiveness of two novel GPR55-selective antagonists on agonist-
mediated GPR55 responses using these in vitro models. 
3. To compare the effects of the endogenous GPR55 agonist (LPI) with synthetic GPR55-
selective agonists. 
4. To determine if LPI mediates neuroprotective effects in degenerating primary cortical 
neurons and if these actions involve GPR55. 
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Chapter Two 
 
Materials and Methods 
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2.1. Materials 
2.1.1. Cell culture: Plasticware and general reagents 
EZBiolab, Carmel, Indiana, USA: 
 Aβ1-40 peptide  
 Reverse Aβ40-1 peptide 
Fisher-Scientific, Loughboriugh, UK: 
 Falcon™ Bacteriological Petri Dishes with Lid (30 mm) 
Greiner bio-one, Stonehouse,UK: 
 25cm2 TC-treated flask with filter cap (T25 TC flask) 
 Cryo.s™, 2 ml, polypropylene, round bottom, internal thread, sterile 
 Pipette tips; 10 μl, 200 μl, 1000 μl 
 Sample container 25x90mm, 30ml, Conical skirted bottom 
 15ml polypropylene centrifuge tube with conical base 
Life Technologies, Paisley, UK: 
 Dulbecco Modified Eagle Medium/F-12 
 Trypsin-Ethylenediaminetetraacetic acid (EDTA) (0.05%), phenol red 
 Phosphate Buffered Solution 
Trinity College Dublin 
 Neurobasal Medium 
 Heat-inactivated horse serum; New Zealand origin 
 Penicillin  
 Streptomycin  
 B27 Supplement 
Merck Millipore Darmstadt, Germany: 
 Millex-GP, 0.22 μm, polyethersulfone, 33 mm, gamma sterilised 
Roche Diagnostics Limited, West Sussex, UK: 
 G418 Solution 
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Sera labs International, West Sussex, UK: 
 Heat inactivated foetal bovine serum; New Zealand origin 
Sigma-Aldrich, Dorset, UK: 
 L-glutamine 
 Poly-D-lysine 
 Sodium Hydroxide 
 HEPES 
 Glucose 
 Paraformaldehyde 
 Dimethyl Sulphoxide 
 Phorbol 12-myristate 13-acetate/12-O-Tetradecanoylphorbol-13-acetate (TPA) 
Trinity College Dublin 
 Poly-L-lysine 
 Saponin 
 Trypsin 
 Trypsin Inhibitor 
 Deoxyribonuclease (DNase) 
 Magnesium Sulphate 
  GlutaMAX  
 Cytosine-arabinofuranoside 
Thermo Fisher Scientific, Waltham, MA, USA: 
 Nalgene™ Cryo 1°C freezing container 
Tocris Bioscience, Bristol, UK: 
 Fura 2-acetoxymethyl (AM) ester 
Vector Laboratories, Peterborough, UK: 
Trinity College Dublin 
 Normal goat serum 
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VWR International, Leicestershire, UK: 
 Dow Corning® high-vacuum silicone grease 
 Sodium Chloride 
 Potassium Chloride 
 Calcium Chloride 
 Magnesium Chloride 
 Coverglasses, round, 9 mm 
 Ethanol 
 
2.1.2. Cell lines 
 Human Embryonic Kidney 293 (HEK293)-AD cells; Life Technologies, Paisley, UK. 
 DU145 prostate cancer cell line;  
 Division of Cancer Research, University of Dundee, Dundee, UK 
and  
 Centre for Diabetes, Blizard Institute, Queen Mary University of London, London, 
UK. 
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2.1.3. Antibodies, probes and dyes 
 
ANTIBODY/DYE 
 
 
COMPANY 
 
DILUTION 
 
University of Dundee 
 
 
Mouse anti-phosphoCREB (serine 
133) clone 10E9 
 
 
Millipore, Watford, Hertfordshire, 
UK 
 
1:250 
 
Alexa Fluor® 488 donkey 
anti-mouse 
 
 
Molecular Probes®, Life 
Technologies, Paisley, UK 
 
1:500 
 
Trinity College Dublin  
 
 
Anti-active caspase-3 primary rabbit 
antibody  
 
 
Promega Corporation, Madison, WI, 
USA 
 
1:250 
 
 
Biotinylated Goat Anti-Rabbit IgG 
Antibody 
 
 
Vector Laboratories, Peterborough, 
UK 
 
1:500 
 
Alexa Fluor® 633 goat anti-rabbit 
 
 
Bio-Sciences Ltd., Dublin, Ireland 
 
 
1:500 
 
Anti-NeuN Antibody, clone A60 
 
 
Millipore, Watford, Hertfordshire, 
UK 
 
1:500 
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Biotinylated Horse Anti-Mouse IgG 
Antibody 
 
Vector Laboratories, Peterborough, 
UK 
 
 
1:1000 
 
 
Alexa Fluor® 488 goat anti-mouse 
 
 
Bio-Sciences Ltd., Dublin, Ireland 
 
 
1:500 
 
Hoechst 33342, Trihydrochloride, 
Trihydrate 
 
Life Technologies, Paisley, UK: 
 
 
1:500 
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2.1.4. Ligands 
 
LIGAND NAME 
 
 
COMPOUND STRUCTURE 
 
COMPANY 
 
L-α-lysophosphatidylinositol  
sodium salt from Glycine max 
(soybean) 
 
 1-Acyl-sn-glycero-3-phospho-(1-D-myo-
inositol) 
  
 
 
 
 
 
Sigma-Aldrich, 
Dorset, UK 
 
 
 
SY-020 
 
 
 
Gift from Prof. 
Tapio 
Nevalainen, 
The University 
of Eastern 
Finland, 
Kuopio, 
Finland 
 
 
12-O-Tetradecanoylphorbol-13-
acetate  
 
Phorbol 12-myristate 13-acetate; 
4β,9α,12β,13α,20-Pentahydroxytiglia-1,6-
dien-3-one 12-tetradecanoate 13-acetate 
 
 
 
 
 
Sigma-Aldrich, 
Dorset, UK 
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LIGAND NAME 
 
 
COMPOUND STRUCTURE 
 
COMPANY 
 
D327-0013  
ML191 (CID23612552) 
 
 3-[1-[1-(4-
methylphenyl)cyclopropanecarbonyl]piperidin-
4-yl]-5-phenyl-1,3,4-oxadiazol-2-one  
 
 
 
 
 
 
ChemDiv, 
San Diego, 
CA, USA 
 
 
C390-0219 
(CID16020046) 
 
4-[4-(3-hydroxyphenyl)-3-(4-methylphenyl)-6-
oxo-1H,4H,5H,6H-pyrrolo[3,4-c]pyrazol-5-yl] 
benzoic acid 
 
 
 
 
 
ChemDiv, 
San Diego, 
CA, USA 
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2.2. Methods 
2.2.1. Cell line maintenance 
hGPR55-HEK293 cells were cultured in Dulbecco's Modified Eagle Medium: Nutrient Mixture 
F-12 media (DMEM/F-12) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 
2mM L-glutamine and 400µg/ml G418 antibiotic and maintained at 37°C with 5% CO2 in a Jouan 
IGO150 CELLlife CO2 Incubator (Thermo Fisher Scientific Inc., MA, USA).  
HEK293 cells were cultured in DMEM/F-12 media supplemented with 10% heat-inactivated fetal 
bovine serum and 2mM L-glutamine and maintained at 37°C with 5% CO2.  
DU145 prostate cancer cells were cultured in DMEM/F-12 media supplemented with 10% heat-
inactivated fetal bovine serum and 2mM L-glutamine and maintained at 37°C with 5%. 
2.2.2. Subculturing cell lines 
Cells were grown in 25cm2/T25
 flasks and subcultured once they had reached 80-90% confluency. 
To subculture cells, 0.5-1ml of pre-warmed 0.05% trypsin-EDTA solution was added to the 
confluent flask. The flask was gently tapped or rocked side to side in a north-east-south-west 
motion to dislodge adherent cells. To aid the cells in lifting off, the flask could be placed in an 
incubator set at 37°C for 1-2 minutes. Cells were checked under the microscope to examine rate 
of detachment. Once the cells had properly lifted and were not clumped together, ~2ml of pre-
warmed culture medium was added to the flask to cease trypsinisation; the serum in the media aids 
in ceasing the trypsinisation reaction. A pre-calculated amount of cell suspension was then pipetted 
into ~4ml of warm media in sterile flasks and/or petri dishes (Falcon) to create an appropriate 
dilution of cells for experimentation. The newly passaged cells were then incubated at 37°C with 
5% CO2 to allow them time to adhere to their container(s). 
2.2.3. Freezing cell lines 
Freezing medium was made up using normal culture medium (with 10% FBS) and 5% dimethyl 
sulphoxide (DMSO). The medium was then stored at 4°C until needed for use. Cells were 
subcultured as described above. The cells were re-suspended in warm culture media and 
transferred to a sterile 15 ml conical tube. The tube was centrifuged at 1000rpm for 3-5 minutes. 
The supernatant was aspirated off using a sterile Pasteur pipette. The pellet was re-suspended in 
1ml of freezing media per vial to be frozen. 1 ml aliquots of the cell-freezing media solution were 
decanted into cryogenic vials and placed into an isopropanol chamber. The chamber was placed 
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into a -80°C freezer so that the temperature of the chamber would drop -1°C per minute overnight. 
The following day the cryovials were removed from the chamber and stored indefinitely at -80°C. 
2.2.4. Thawing cell lines 
Warm culture medium (~5ml) was decanted into a T25 flask. The flask was then kept warm in an 
incubator until needed. A cryovial was removed from the -80°C freezer and placed into an 
incubator set at 37°C until almost all of the solution inside had thawed. The outside of the vial was 
gently sprayed with ethanol and the vial was placed in the fumehood. The T25 flask was retrieved 
from the incubator. The cap of the cryovial was opened and, using a P1000 (Gilson, Inc., 
Bedfordshire, UK), its contents were gently pipetted into the pre-warmed media in the T25 flask. 
The flask was gently rocked to allow for even cell coverage. The flask was placed into a 37°C 
incubator with 5% CO2. 
After about an hour (or until the cells had adhered), the flask was removed from the incubator. 
Around three-quarters of the medium was aspirated away using a P1000 and decanted into a new 
T25 flask which already contained 4-5 ml of warm culture medium. About 4-5 ml of fresh, warm 
culture medium was then added to the first flask. The new flask acted as a recovery and was diluted 
with more media because it contained more DMSO (DMSO is toxic to cells). The old flask now 
contained an attached cell line and little to no DMSO. 
2.2.5. Preparation of cells for experimentation 
To prepare cell lines for experimentation, petri dishes were lined with coverslips that were pre-
coated in poly-D-lysine. To achieve this, 9mm coverslips were placed into a sterile 50 ml Falcon 
tube and washed twice with 70% ethanol followed by washing x2 with distilled H2O (dH2O). The 
water was aspirated away and poly-D-lysine (20µg/ml) was made up (diluted in dH2O) and poured 
over the coverslips. The Falcon tube was then placed on a rocker and the coverslips were incubated 
for 1 hour or longer. The coverslips were then stored at 4°C until required and used within a 
maximum of two weeks. 
To plate out cells, confluent flasks were subcultured as described before. The cell suspension was 
diluted appropriately by pipetting a pre-determined amount of the suspension into warm culture 
medium in coverslip-lined petri dishes. This took place 24-72 hours in advance of experimentation. 
The cells were then maintained at 37°C with 5% CO2 in a cell culture incubator to facilitate their 
adherence. 
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The night before an experiment was due to take place, cells were incubated in serum-free medium 
supplemented with 2mM L-glutamine. Serum-free medium was used because serum-derived 
lipoproteins and other bioactive components such as sphingosine 1-phosphate (S1P) are capable 
of activating membrane surface proteins and proteases (Benaud et al., 2002) as well as Rho 
GTPases (Dupont et al., 2011). It was therefore crucial to attempt to eliminate the possibility of 
receptor activation and internalisation before experimentation. 
2.2.6. Preparation of primary neuronal cultures 
Cortical neuronal cultures were prepared from 1-day-old male Wistar rats (BioResources Unit, 
Trinity College, Dublin 2, Ireland). The rats were decapitated and the cortices dissected. The 
meninges were removed from the cortices using a curved forceps. The cortical tissue was chopped 
into smaller pieces of tissue using a sterile razor blade. Using a sterile Pasteur pipette, the tissue 
was aspirated and transferred into a sterile 15 ml conical tube and incubated with trypsin diluted 
in PBS (0.3% (w/v)) for 25 minutes at 37°C with 5% CO2 in a cell incubator (AutoFlow NU-4750 
Water-Jacket CO2 Incubator, NuAire). The tube was removed from the incubator and a solution 
of trypsin inhibitor diluted in PBS (0.1%) was added to the tissue. The tube was inverted 
repeatedly. The tissue was allowed to settle and the supernatant was aspirated away using a Pasteur 
pipette. A solution of trypsin inhibitor (0.1%(w/v)), deoxyribonuclease (DNase; 0.2mg/ml) and 
magnesium sulphate (0.1 M) was added to the tissue and the tube was inverted repeatedly. The 
tissue was triturated repeatedly using a sterile pipette and passed through a sterile mesh filter (0.2 
µm). The tissue was centrifuged at 2000 rpm (Sigma 2-16K model, Sigma-Aldrich, Dorset, UK) 
for 3 minutes at 20°C. The supernatant was aspirated off and the pellet was re-suspended in warm 
neurobasal medium (NBM) supplemented with heat-inactivated horse serum, penicillin (100 
units/ml), streptomycin (100 units/ml), GlutaMAX (2 mM), and B27 (1%(v/v)). The cell-medium 
suspension was pipetted out onto coverslips pre-coated in poly-L-lysine (40 µg/ml). These 
coverslips lined 24-well plates. The plate(s) were maintained at 37°C with 5% CO2 in a cell culture 
incubator for 3 hours. After 3 hours, the cells were flooded with 300 µl of warm culture medium. 
After 3-4 days, the media was removed from the plates and replaced with warm NBM containing 
cytosine-arabinofuranoside (5 µg/ml) in order to prevent proliferation of non-neuronal cells. The 
plates were incubated in this medium at 37°C with 5% CO2 overnight. The next day, the media 
was removed and replaced with normal NBM supplemented with B27. The culture medium was 
replaced every 24-48 hours prior to treatment. 
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2.2.7. Treatment of neuronal cells 
Aβ1-40 peptide was diluted in 84% PBS and 16% double dH2O and allowed to aggregate for 48 
hours at 37°C. The peptide was made up as a 200 µM stock and stored at -20°C. For treatment of 
cortical neurons, Aβ was diluted to a working concentration of 1 µM in pre-warmed NBM. Control 
treatment groups were incubated in normal NBM only. Drug treatments were diluted to a working 
concentration using NBM. For treatment groups that were exposed to Aβ, cells were initially 
exposed to ligands for 30 minutes without Aβ. Following this, the ligand treatment-media was 
removed and replaced with warm NBM containing the same drug treatments and Aβ (1 µM). Cells 
were maintained at 37°C with 5% CO2 in a cell culture incubator for a further 72 hours. 
 
2.3. Experimental Protocols 
2.3.1. Ca2+imaging 
Cells that were attached to coverslips coated in poly-D-lysine and incubated in serum-free medium 
were washed once with 1x HEPES-buffered saline (HBS in mM:  NaCl 135; KCl 5; MgCl2 1; CaCl2 
1; HEPES 10; Glucose 10; pH 7.4).  The cells were loaded with bis-fura 2-acetoxymethyl (AM) 
ester at 6 µM for 45 minutes-1 hour and were left to incubate in darkness at room temperature. 
The cells were washed x2 in HBS and left for 15-30 minutes to allow for the de-esterification of 
the AM groups.  
Prior to imaging, the tubes required for perfusion were washed for 10 minutes with 70% ethanol, 
followed by a 10 minute wash with distilled water. The tubes were then perfused with 1x HBS for 
10-15 minutes at 30°C. A single coverslip containing cells loaded with fura-2 was adhered to the 
bottom surface of a Falcon™ petri dish (30mm) using high vacuum grease. The open petri dish 
was then mounted on a microscopic stage. A digital epifluorescence imaging system mounted on 
an Olympus BX50WI microscope (Olympus, Tokyo, Japan) was used to measure changes in 
intracellular Ca2+ signal. Cells were excited at 350 and 380 nm, with emission detected above 500 
nm. Changes in the fura-2 fluorescence ratio were visualised using MetaFluor® offline imaging 
software (Molecular Devices Corporation, CA, USA). Cells were perfused with ligand solution 
typically for ~5 minutes at a rate of 2 ml/min. Recordings were made at 5 second intervals. 
Experiments were conducted as follows: firstly, cells were continuously perfused with HBS for 10-
15 minutes to obtain a baseline. Then (1) if only agonist responses were being examined, a pre-
determined amount of agonist solution was applied and allowed to perfuse over the cells to allow 
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for an increase in Ca2+, as visualised by a change in fluorescence ratio. Cells were then washed for 
30 minutes with HBS to completely rid the tubing of stimulant solution before beginning another 
experiment with another coverslip; (2) if antagonist effectiveness was being examined, a pre-
determined amount of antagonist solution was applied and allowed to perfuse over the cells. 
Immediately after this, a solution was applied which contained both agonist and antagonist. After 
this, a solution of antagonist alone was again applied to inhibit any possible change in [Ca2+]i that 
may have occurred during the prior period. The cells were washed for 30 minutes or more in HBS 
to rid the tubing of stimulant/antagonist. If there were no responses during ligand application or 
during the washout period, agonist solution was allowed to perfuse over the cells in order to 
visualise cellular responses and recovery from antagonist perfusion. 
2.3.2. Immunocytochemistry 
Phospho-CREB – Cultured cell lines were attached to coverslips coated in poly-D-lysine (20 µg/ml) 
and incubated in serum-free media overnight at 37°C with 5% CO2. The next day, the cells were 
washed three times in 1x HBS. Agonist ligands were applied for 25 min at 37°C and 0% CO2. 
Antagonists were applied for 30 min prior to co-application with agonist ligands for a further 25 
min. The cells were then fixed in ice cold methanol for 5 minutes at -20°C. The cells were washed 
x3 in HBS and blocked for 30 minutes in 5% Marvel® milk powder (diluted in HBS; Premier 
Foods, Hertfordshire, UK) at room temperature. After washing x3 in HBS, the cells were 
incubated with primary Mouse anti-phospho-CREB monoclonal antibody at 1:250 dilution for 1 
hour at room temperature. The cells were washed x3 in HBS. A Donkey anti-mouse secondary 
antibody conjugated with AlexaFluor® 488 dye at 1:500 dilution was applied to the coverslips and 
they were left to incubate at room temperature in darkness for 30 minutes. Cells were washed x3 
with HBS. The coverslips were affixed to glass slides (VWR international, Leicestershire, UK) 
using Fluoromount-G mounting media (Southern Biotech, Birmingham, AL, USA) and allowed 
to set for <1 hour in darkness. An Axiovert 200M inverted confocal microscope (Zeiss, LSM-510-
META, Carl Zeiss, Cambridge, UK) was used to examine the incorporated fluorophores. 
In CREB experiments, 12-O-tetradecanoylphorbol-13-acetate (TPA) was used as a control 
stimulus. TPA is a specific activator of PKC and has previously been found to induce the 
transcription of CREB in mouse embryonic fibroblast cells (Johannessen et al., 2004). 
Caspase-3 – Cultured primary cortical neurons attached to poly-L-lysine coated coverslips (40 
µg/ml) were permeabilised using 1% saponin (diluted in dH2O) for 5 minutes at room 
temperature. The cells were washed twice with PBS. The neurons were incubated in normal goat 
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serum (10%) for 2 hours at room temperature. The cells were washed x2 in PBS. The cells were 
incubated overnight at 4°C with anti-active caspase-3 primary rabbit antibody that also contained 
10% normal goat serum (1:250 dilution). The next day, the neurons were washed x3 with PBS. 
They were incubated with secondary biotinylated goat anti-rabbit antibody (1:500; 20% normal 
goat serum included) for 90 minutes at room temperature. The cells were washed x3 with PBS. 
The cells were incubated with an Alexa Fluor® 633 goat anti-rabbit fluorescent probe (1:500; 10% 
normal goat serum included) for 40 minutes at room temperature. Following this they were washed 
x3 with PBS. The cells were blocked again using 5% normal goat serum and incubated at room 
temperature for 2 hours. They were washed x2 with PBS. The neurons were double-stained for 
NeuN at a 1:500 dilution (10% normal goat serum included) and incubated at 4°C overnight. The 
following day, the cells were incubated in secondary horse anti-mouse antibody (1:1000 dilution; 
20% normal goat serum included) for 90 minutes at room temperature. They were washed x3 with 
PBS. The neurons were incubated with an Alexa Fluor® 488 goat anti-mouse fluorescent probe 
(1:500 dilution; 10% normal goat serum included) for 40 minutes at room temperature. They were 
then washed x3 with PBS. The neurons were incubated with Hoechst fluorescent dye (1:500 
dilution; Invitrogen, CA, USA) for 15 minutes at room temperature. The Hoescht dye was 
removed from the coverslips and they were washed once with PBS. Excess PBS was removed and 
the coverslips were affixed to glass slides (Ramboldi, Limassol, Cyprus) using Vectashield 
mounting media (Vector Laboratories, Peterborough, UK). The mounting media protected against 
photobleaching. The edges of the coverslips were sealed using clear nail polish and the slides were 
stored in darkness at 4°C until needed for analysis. An Axiovert 200M inverted confocal 
microscope (Zeiss, LSM-510-META, Carl Zeiss, Cambridge, UK) was used to examine the 
incorporated fluorophores.  
 
2.4. Sample Analysis and Quantification 
2.4.1. Peak Ca2+ response height 
To analyse the extent of Ca2+ mobilisation during an experiment, raw data was extracted from 
cellular recordings using MetaFluor® offline software (Molecular Devices Corporation, CA, USA). 
The background was subtracted from these recordings. The raw data was then transferred to 
Origin 7 software (OriginLab Corporation, Stoke Mandeville, UK) where cell traces were created. 
The response height was obtained by measuring the raw data from the timepoint where the ligand 
was first applied up until 10 minutes after the ligand was removed during the washout. A baseline 
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height reading was also obtained by measuring the raw data from 5 minutes before the ligand was 
first applied. The following calculation was then used: 
Peak response height = Response height – Baseline height 
An average peak response height was calculated from the cells (in this case 9 cells per experiment). 
An example trace of a typical Ca2+ imaging experiment can be observed in Figure 2.4.1. One trace 
represents one cell. Therefore, if there are multiple traces that are differentially coloured in one 
figure, each trace represents one cell recorded during one experiment. In this study, the release of 
Ca2+ from intracellular stores measured with Ca2+ imaging shall be referred to as an increase in Ca2+ 
signal. 
The peak response height data of Ca2+ imaging experiments were transferred to GraphPad Prism 
4 software (GraphPad Software, Inc., CA, USA) in order to construct histograms. 
 
 
 
 
Ligand application
Peak response height
Baseline
0.2 units
5 min
Figure 2.4.1: An example trace of one cell recorded during a Ca2+ imaging 
experiment. 
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2.4.2. Phospho-CREB nuclear fluorescence 
As previously stated, cells on coverslips that underwent immunocytochemical staining were affixed 
to glass slides and images were taken using a confocal microscope. Nuclear fluorescence 
measurements of phospho-CREB were taken from these images using ImageJ free software 
(http://imagej.nih.gov/ij/; National Institutes of Health) in order to provide quantifiable data. To 
measure nuclear fluorescence, the following settings were applied in ImageJ: the ‘Set 
Measurements’ option was selected from the drop-down ‘Analyse’ menu on the toolbar. In the 
‘Set Measurements’ tab, the boxes next to ‘Area’, ‘Min and max gray value’ ‘Integrated density’, 
‘Mean gray value’ and ‘Add to overlay’ were ticked. ‘Redirect to’ was set to ‘None’ and ‘Decimal 
places’ were set to ‘3’. Once this was completed, ‘OK’ was clicked (See Figure. 2.3.1). 
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An image of pCREB-stained cells, originally obtained using Zeiss LSM 510 software, was opened 
on ImageJ. On the main toolbar, the ‘Polygon’ option was selected. The author manually traced 
shapes on the background of the fluorescent image. By clicking ‘m’ on the keyboard, this brought 
up a ‘Results’ tab which detailed various parameters of the area just measured. The author then 
clicked ‘>’ to switch to the brightfield view. In this view, lines were traced around the nuclei of 
cells using the ‘polygon’ tool because the nuclei were more distinct from the cytoplasm in this 
view. It also aided in keeping the recordings unbiased because the author did not know if the nuclei 
positively expressed pCREB in the brightfield view. The nuclear measurements were recorded by 
switching back to the fluorescent view of the image and clicking ‘m’ again (See Figure 2.3.2). 
 
 
 
 
 
 
Figure 2.4.2: Settings required in order to measure nuclear fluorescence in 
ImageJ software.  
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The nuclear measurements were transferred to an excel file. An average fluorescence value was 
obtained from the three background areas measured by averaging the ‘mean’ values of each area. 
Background measurement
Polygon selection
Area of nucleus
measured
Mean fluorescence
values
Integrated density 
values
Figure 2.4.3: Settings required in order to obtain raw data for analysis. 
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The corrected total nuclear fluorescence (CTNF) was then obtained from the cells using the 
following formula: 
CTNF = Integrated Density – (Area of nucleus x Mean of background) 
This formula ensured that the size of the nuclear area in number of pixels, the integrated intensity 
of all pixels within the nuclear area and the average intensity per pixel were all corrected for 
background. Essentially, CTNF is a measurement of fluorescence intensity within a cell nucleus 
minus the background fluorescent intensity (Bülow et al., 2014; Nederlof et al., 1992; Potapova et 
al., 2011). Data displayed on histograms was created by normalising CTNF values for an 
experiment against the mean 1 µM TPA value of that experiment. Histograms were then created 
using GraphPad Prism 4 software (GraphPad Software, Inc., CA, USA). Twelve nuclei were 
selected from each pCREB experiment in order to visualise the quantified data on graphs. 
 
2.4.3. Caspase-3 fluorescence intensity 
Coverslips fixed with cortical neurons that were stained for caspase-3 and affixed to glass slides 
were analysed and images taken using a confocal microscope (Zeiss, LSM-510-META, Carl Zeiss, 
Cambridge, UK). Multiple images were taken for each treatment group at both a low magnification 
(40x) and a high magnification (63x). Different wavelengths were used that corresponded to the 
antibodies and stain materials used on the neurons during prior immunocytochemical staining. 
Images were taken at 633 nm for capase-3 detection, at 488 nm for NeuN detection and UV light 
was used to detect the Hoechst stain.  
Caspase-3 fluorescence values were obtained using LSM-510 image examiner software (Zeiss, Carl 
Zeiss, Cambridge, UK). An image taken at 63x magnification was opened on-screen. Images at 
63x magnification were chosen for measurement because there was greater detail and the 
fluorescence was more consistent than in images taken at 40x magnification. Once an image was 
open, the ‘Histogram’ tab was clicked on the right-hand panel. Using a line tool, lines were drawn 
around the cellular bodies of the neurons (not the processes). Once a complete shape was drawn 
around the cellular body, a fluorescence value for that measured area was given on-screen by 
clicking the ‘Statistics’ tab on the right hand panel. This process was repeated for other neurons in 
the image and again for other images taken of neurons in each treatment group. Background 
measurements were not taken. 
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Fluorescence values were transferred to an excel file and the average fluorescence intensity value 
was obtained for each treatment group in each experiment. In this study, 7 neuronal cellular bodies 
were measured per treatment group and per experiment. Histograms of the data were then created 
using GraphPad Prism 4 software (GraphPad Software, Inc., CA, USA). 
 
2.5. Statistical Analyses 
2.5.1. Ca2+imaging data analysis 
Statistical analyses were performed using a paired and two-tailed Student’s t test in order to 
compare differences in the effects of ligands treatments on the same population of cells in the 
same experiment. If experiments were conducted in different cell populations, then a Mann-
Whitney U test or One-Way Analysis of Variance (ANOVA) with Bonferroni’s post hoc test were 
applied. P < 0.05 was considered a significant result. Data was obtained from 9 cells in a field per 
experiment. 
 
2.5.2. Phospho-CREB nuclear fluorescence data analysis 
Statistical analyses were performed using One-Way ANOVA. If the results were significant, 
Bonferroni’s Post hoc test was applied to determine which groups were significantly different from 
one another. A Mann-Whitney U test was applied if only two treatment groups were being 
compared. P < 0.05 was considered a significant result. Fluorescence data was obtained from 12 
cellular nuclei in a field per experiment. 
 
2.5.3. Caspase-3 fluorescence data analysis 
Statistical analyses were performed using One-Way ANOVA. Fluorescence data was obtained 
from the cellular bodies of 7 cells in a field per experiment. 
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Chapter Three 
 
Results 
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3.1.1. LPI stimulation leads to an increase in intracellular Ca2+ release in the hGPR55-
HEK293 cell line. 
GPR55 stimulation has previously been shown to lead to the release of Ca2+ from intracellular ER 
stores in hGPR55-HEK293 cells via a Gα13-RhoA-ROCK signalling pathway (Henstridge et al., 
2009a). In the hGPR55-HEK293 cell line, perfusion with a supramaximal concentration of LPI 
led to an increase in Ca2+ signal (1 μM LPI = 0.171 ± 0.035 ratio units; Figure 3.1.1A). 
Recombinant HEK293 cells were compared to HEK293 control cells. Upon stimulation with 1 
µM LPI, these cells did not produce an increase in Ca2+ signal (1 μM LPI = 0.059 ± 0.003 ratio 
units; Figure 3.1.1Bi). This corroborates with previous data (Henstridge et al., 2009a). However, 
stimulation with 10 µM LPI resulted in an increase in Ca2+ signal (10 μM LPI = 0.103 ± 0.016 ratio 
units; Figure 3.1.1Bii). This is in contrast to findings previously reported (Henstridge et al., 2009a), 
but it is worth noting that 10 µM LPI is a very high dose of ligand and could therefore be inducing 
an increase in intracellular Ca2+ independently of GPR55. Due to time constraints, GPR55 
antagonists were not tested against LPI (10 µM) in control HEK293 cells. This should be 
investigated in future. Sphingosine-1-phosphate (S1P) was applied to control HEK293 cells (1 µM 
S1P = 0.366 ± 0.109 ratio units; Figure 3.1.1Biii) and acted as a positive control ligand in order to 
show an increase in Ca2+ signal (Gupta et al., 2012). 
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3.1.2. CREB phosphorylation is induced by LPI in hGPR55-HEK293 cells but not in 
control HEK293 cells. 
CREB is a member of a family of proteins that act as transcription factors. Phosphorylation of 
CREB causes it to translocate from the cell cytoplasm into the nucleus. In the nucleus, phospho-
CREB activates CREB-mediated gene transcription e.g. c-Fos, which can lead to downstream 
effects such as cell proliferation (Carlezon Jr et al., 2005; Shaywitz & Greenberg, 1999; Stevenson 
et al., 2001).  
In order to delineate if LPI mediates its effects via GPR55, CREB phosphorylation was compared 
in both stably transfected HEK293-AD cells (hGPR55-HEK293) and in control HEK293-AD 
cells. Cells treated with LPI (1 µM) for 25 minutes exhibited evidence of substantial CREB 
phosphorylation, which is indicated by a bright green nucleus (1 µM LPI = 0.698 ± 0.173 units; 
Figure 3.1.2C). A 25 minute application was chosen because it has been previously shown that this 
time point induces maximal pCREB activation in hGPR55-HEK293 cells (Henstridge, 2009). The 
cells also became rounder in morphology. In comparison, cells treated with DMSO (1:1000) for 
25 minutes failed to show signs of CREB phosphorylation and the cells remained flat in 
morphology (DMSO = 0.329 ± 0.038 units; Figure 3.1.2A). In Figure 3.1.2B, it can be seen that 
treatment of cells with 1 µM 12-O-tetradecanoylphorbol-13-acetate (TPA) for 25 minutes resulted 
in robust CREB phosphorylation (1 µM TPA = 1.000 units).  
Treatment with 1 µM LPI for 25 minutes did not cause CREB phosphorylation to occur in control 
HEK293 cells (HEK293, 1 µM LPI = 0.324 ± 0.033 units; Figure 3.1.2F). The cells were 
comparable to cells exposed to DMSO (HEK293, DMSO = 0.365 ± 0.212 units; Figure 3.1.2D). 
To test if control HEK293 cells were responsive, cells were treated with 1 µM TPA, which induced 
robust CREB phosphorylation (HEK293, 1 µM TPA = 1.000 units; Figure 3.1.2E).  
Figure 3.1.1: LPI induces an increase in Ca2+ signal in hGPR55-HEK293 
cells. (A-B) Representative traces of cell recordings from individual hGPR55-
HEK293 cells and control HEK293 cells treated with various ligands. Each trace 
from each part of the figure represents one cell exposed to one ligand in one 
experiment. hGPR55-HEK293 cells were treated with (A) 1 µM LPI. HEK293 
cells were treated with (Bi) 1 µM LPI, (Bii) 10 µM LPI, (Biii) 1 µM S1P. Data is 
represented as mean ± standard error of the mean (SEM). n = 3. Mean peak 
response measured from 9 cells per experiment. 
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3.1.3. The GPR55 antagonist D327-0013 inhibits LPI-induced increases in Ca2+ signal in 
the hGPR55-HEK293 cell line. 
At 10 µM D327-0013 did not cause an increase in Ca2+ signal when applied alone (10 µM D327-
0013 = 0.057 ± 0.006 ratio units; Figure 3.1.3Aii). D327-0013 markedly inhibited Ca2+ responses 
to LPI (1 µM) by 90.4 ± 0% (3 µM D327-0013 + 1 µM LPI = 0.029 ± 0.010 ratio units; later 1 
µM LPI treatment = 0.303 ± 0.041 ratio units). This contrasts to cells exposed to 1 µM LPI in 
separate populations of cells, where there was a potent increase in Ca2+ signal (1 µM LPI = 0.192 
± 0.020 ratio units; Figure 3.1.3Ai) A paired Student’s t test was performed and indicated that 3 
µM D327-0013 significantly inhibited 1 µM LPI compared to when the same cells were exposed 
DMSO TPA 1 μM LPI 1 μM
hGPR55-HEK293
B
HEK293
A
DMSO TPA 1 μM
HEK293
LPI 1 μM
HEK293
C
D E F
hGPR55-HEK293 hGPR55-HEK293
Figure 3.1.2: CREB phosphorylation is induced by LPI in hGPR55-HEK293 
cells. Phosphorylated cAMP response element-binding protein (CREB) labelling in 
hGPR55-HEK293 cells treated with (A) DMSO; (B) 1 μM TPA and (C) 1 μM LPI, and 
labelling in HEK293 cells treated with (D) DMSO; (E) 1 μM TPA and (F) 1 μM LPI. 
Rounded-up cells are denoted by red arrows. A-E, n= 3, F, n =2. Fluorescence 
intensities measured from 12 cellular nuclei per experiment. Scale bar = 20 μm. 
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to only 1 µM LPI later on in the experiment (*P < 0.0131; Figure 3.1.3Aiii, Biii).. A lower 
concentration of 1 µM D327-0013 inhibited LPI-induced increase in Ca2+ signal  by 75.4 ± 0% (1 
µM D327-0013 + 1 µM LPI = 0.048 ± 0.002 ratio units; later 1 µM LPI treatment = 0.194 ± 0.061 
ratio units). A paired Student’s t test was performed and indicated that 1 µM D327-0013 did not 
significantly inhibit 1 µM LPI compared to when the same cells were exposed to only 1 µM LPI 
later on in the experiment (P < 0.2477; Figure 3.1.4Bii).  
When cells were exposed to 1-3 µM D327-0013 and 1 µM LPI and were compared to cells exposed 
to 1 µM LPI in separate populations, there was a marked inhibition in Ca2+ signal (3 µM D327-
0013 + 1 µM LPI = 0.019 ± 0.010 ratio units; 1 µM D327-0013 + 1 µM LPI = 0.048 ± 0.002 ratio 
units; 1 µM LPI, separate experiment = 0.192 ± 0.020 ratio units; Figure 3.1.3Ai). A One-Way 
ANOVA and Bonferroni’s post hoc test were performed on this data and determined that 1-3 µM 
D327-0013 significantly inhibited LPI-induced increases in Ca2+ signal compared to when cells 
were exposed to 1 µM LPI only in separate cell populations [F(2,3) = 650.9, ***P < 0.001] (Figure 
3.1.3Biv).   
No antagonism of LPI-induced responses were observed when nanomolar concentrations of 
D327-0013 were applied (300 nM D327-0013 + 1 µM LPI = 0.519 ± 0.287 ratio units; later 1 µM 
LPI treatment = 0.494 ± 0.368 ratio units; Figure 3.1.3Aii). A paired Student’s t test was performed 
and indicated that 300nM D327-0013 did not significantly inhibit 1 µM LPI compared to when 
the same cells were exposed to just 1 µM LPI later on in the experiment (P < 0.807206). A One-
Way ANOVA and a Bonferroni post hoc test were performed on this data and determined that 
300 nM D327-0013 did not inhibit LPI-induced increases in Ca2+ signal compared to when cells 
were exposed to 1 µM LPI only in separate populations of cells (Figure 3.1.4Biv). 
  
48 
 
 
M
M
 +
 L
P
I 1
 

D
32
7-
00
13
 1
 
M
LP
I 1
 
0.0
0.1
0.2
0.3
M
e
a
n
 P
e
a
k
 R
e
s
p
o
n
s
e
LPI 1 M
D327-0013 10 M
LPI 1 MD327-0013 300 nM
LPI 1 M LPI 1 MD327-0013 3 M
LPI 1 M
0
.2
 u
n
it
s
5 min
0
.2
 u
n
it
s
5 min
0
.2
 u
n
it
s
5 min
A
(ii)
B
(i)
(iii) (iv)
0
.2
 u
n
it
s
5 min
(ii)(i)
(iii)
(iv)
M
D
32
7-
00
13
 3
00
 n
M
 +
 L
P
I 1
 
M
LP
I 1
 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
M
e
a
n
 P
e
a
k
 R
e
s
p
o
n
s
e
M
M
 +
 L
P
I 1
 

D
32
7-
00
13
 3
 
M
LP
I 1
 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
*
M
e
a
n
 P
e
a
k
 R
e
s
p
o
n
s
e
M
 +
 L
PI
 1
 

D
32
7-
00
13
 3
00
 n
M
M
M
 +
 L
P
I 1
 

D
32
7-
00
13
 1
 
M
 

M
 +
 L
P
I 1
 

D
32
7-
00
13
 3
 
M
LP
I 1
 
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
***
***
#
M
e
a
n
 P
e
a
k
 R
e
s
p
o
n
s
e
49 
 
 
 
 
 
 
 
 
 
3.1.4. The GPR55 antagonist D327-0013 attenuates LPI-induced CREB phosphorylation 
levels in the hGPR55-HEK293 cell line. 
The antagonistic effects of 3-10 µM D327-0013 against 1 µM LPI were analysed in relation to 
levels of pCREB fluorescence. D327-0013 (10 µM) inhibited 1 µM LPI by 59.9 ± 0% (10 µM 
D327-0013 alone = 0.310 ± 0.020 units; 10 µM D327-0013 + 1 µM LPI = 0.276 ± 0.004 units; 
Figure 3.1.4Aiv and Av). A concentration of 3 µM D327-0013 inhibited 1 µM LPI by 37.3 ± 0% 
(3 µM D327-0013 alone = 0.298 ± 0.041 units; 3 µM D327-0013 + 1 µM LPI = 0.431 ± 0.041 
units). D327-0013 (1 µM) failed to inhibit LPI-induced CREB phosphorylation (1 µM D327-0013 
alone = 0.261 units; 1 µM D327-0013 + 1 µM LPI = 0.850 units; Figure 3.1.4Avi and Avii). A 
histogram of fluorescence intensity data can be observed in Figure 3.1.4B. A One-Way ANOVA 
was applied with Bonferroni’s post hoc test to determine if D327-0013 had a significant inhibitory 
 
Figure 3.1.3: The GPR55 antagonist D327-0013 inhibits LPI-induced 
increases in Ca2+ signal in hGPR55-HEK293 cells. (Ai-iv) Representative 
traces of hGPR55-HEK293 cells treated with ligands. (Ai) A trace representing 
the response of one cell to 1 µM LPI treatment alone. (Aii) 10 µM D327-0013 
did not induce Ca2+ release alone. (Aiii-iv) Cells were treated with D327-0013 
at differing concentrations. LPI was co-perfused over the cells during antagonist 
exposure. In (iii), each differently coloured trace represents one cell. (Bi-iv) 
Histograms representing changes in Ca2+ signal in cells exposed to 300nM-3 
µM of D327-0013. A paired Student’s t test was performed to compare cell 
treatment with D327-0013 and 1 µM LPI, with later LPI (1 µM)-only treatment 
in the same population of cells. * = D327-0013 significantly inhibited LPI-
induced increases in cellular Ca2+ signal compared to LPI application alone later 
on in the experiment (P < 0.0131). A One-Way ANOVA followed by a 
Bonferroni post hoc test was performed to compare cell treatment with D327-
0013 and 1 µM LPI, with cell exposure to 1 µM LPI only in separate populations 
of cells. *** = D327-0013 significantly inhibited LPI-induced increases in 
cellular Ca2+ signal compared to LPI application alone in separate populations 
(P < 0.001) . # = 3 µM D327-0013 inhibition of 1 µM LPI-induced changes in 
Ca2+ signal  is significantly different to 1 µM D327-0013-mediated inhibition of 
LPI-induced changes in Ca2+ signal in different populations of cells (P < 0.05). 
Data is represented as mean ± SEM. Ai-ii, iv, Biii, n =3; Aiii, Bi-ii, iv, n =2. 
Mean peak response measured from 9 cells per experiment. 
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effect on LPI-induced CREB phosphorylation. The post hoc indicated that there was no 
significant difference in nuclear pCREB fluorescence between each treatment group. In 
comparison, cells treated with 1 µM LPI underwent robust CREB phosphorylation (1 µM LPI = 
0.698 ± 0.173 units; Figure 3.1.4Aiii). DMSO-treated cells did not exhibit increased pCREB 
fluorescence (DMSO = 0.329 ± 0.038 units; Figure 3.1.4Ai). Cells stimulated with TPA showed 
evidence of robust CREB phosphorylation (1 µM TPA = 1.000 units; Figure 3.1.4Aii). 
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3.1.5. The GPR55 antagonist C390-0219 inhibits LPI-induced increases in Ca2+ signal in 
the hGPR55-HEK293 cell line. 
Kargl et al. (2013) observed that the GPR55 antagonist C390-0219 inhibited LPI-mediated Ca2+ 
release in a concentration-dependent manner in hGPR55-HEK293 cells. Similar experiments were 
performed in the current study. At 10 µM C390-0219 did not cause an increase in Ca2+ signal when 
applied alone (10 µM C390-0219 = 0.053 ± 0.004 ratio units; Figure 3.1.5Aii). C390-0219 (3 µM) 
markedly inhibited responses to LPI (1 µM) by 75.8 ± 0% (3 µM C390-0219 + 1 µM LPI = 0.059 
± 0.013 ratio units; Figure 3.1.5Aiv). The effects of the antagonist were reversed following a 30 
minute washout period.  This contrasts to cells exposed to 1 µM LPI in separate populations of 
cells, where there was a potent increase in Ca2+ signal (1 µM LPI = 0.192 ± 0.020 ratio units; Figure 
3.1.3Ai). A paired Student’s t test was performed and the t test indicated that 3 µM C390-0219 
significantly inhibited 1 µM LPI in comparison to when the same cells were exposed 1 µM LPI 
later on in the same experiment (*P < 0.0157) (Figure 3.1.5Bi). C390-0219 (1 µM and 100 nM) did 
not antagonise LPI signalling (1 µM C390-0219 + 1 µM LPI = 0.090 ratio units, n =1; 100 nM 
C390-0219 + 1 µM LPI, n = 1 = 0.288 ± 0.218 ratio units; Figure 3.1.5Aiii).  
A One-Way ANOVA and a Bonferroni post hoc test were performed on this data and determined 
that 100 nM and 3 µM C390-0219 did not significantly inhibit LPI-induced increases in Ca2+ signal 
compared to when cells were exposed to 1 µM LPI only in separate populations of cells (Figure 
3.1.5Bii). Statistical tests could not be performed on cells exposed to 1 µM C390-0219 because 
only an n = 1 was obtained (Figure 3.1.5Bii). 
Figure 3.1.4: The GPR55 antagonist D327-0013 GPR55 attenuates LPI-
induced CREB phosphorylation levels in hGPR55-HEK293 cells. (A) 
Phosphorylated CREB labelling in hGPR55-HEK 293 cells treated with (i) 
DMSO; (ii) 1 μM TPA; (iii) 1 μM LPI; (iv) 10 μM D327-0013; (v) 10 μM D327-
0013 + 1 μM LPI; (vi) 1 μM D327-0013 and (vii) 1 μM D327-0013 + 1 μM LPI. 
(B) Histogram representing the effects of D327-0013 and LPI on phospho-
CREB fluorescence. A One-Way ANOVA and Bonferroni’s post hoc were 
performed to determine if there was a significant difference in pCREB 
fluorescence between each treatment group. The differences in fluorescence 
were not significant. Data is represented as mean ± SEM. Aiv-v, n = 2; Avi-vii, 
n =1; all other treatment groups, n = 3. Fluorescence intensities measured from 
12 cellular nuclei per experiment. Scale bar = 20 μm. 
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3.1.6. The GPR55 antagonist C390-0219 attenuates LPI-induced CREB phosphorylation 
levels in the hGPR55-HEK293 cell line. 
The putative GPR55 antagonist C390-0219 was not capable of antagonising CB1-mediated CREB 
activation in CB1-HEK293 cells. It also did not induce CREB phosphorylation when applied alone 
in the CB1-HEK293 and control HEK293 cell lines (Kargl et al., 2013). This suggests that C390-
0219 does not mediate antagonistic effects via CB1 receptor. It was therefore of interest to 
investigate if C390-0219 could inhibit agonist-induced CREB phosphorylation via GPR55.  
Concentrations of 1 µM-10 µM C390-0219 and 1 µM LPI were tested in a CREB phosphorylation 
assay (10 µM C390-0219 alone = 0.202 ± 0.035 units; 10 µM C390-0219 + 1 µM LPI = 0.262 ± 
0.017 units; 61.9 ± 0% inhibition; Figure 3.1.6Avi-v; 3 µM C390-0219 alone = 0.260 ± 0.038 units; 
3 µM C390-0219 + 1 µM LPI = 0.348 ± 0.120 units; 49.4 ± 0.1% inhibition; Figure 3.1.5B; 1 µM 
C390-0219 alone = 0.229 ± 0.05 units; 1 µM C390-0219 + 1 µM LPI = 0.650 ± 0.125 units; Figure 
3.1.6Avi-vii). A histogram of pCREB fluorescence intensities can be observed in Figure 3.1.6B. A 
One-Way ANOVA deduced that there was a significant difference in fluorescence intensities 
between the groups analysed [F(3,8) = 6.405, *P < 0.0161]. A Bonferroni’s Post hoc test was applied 
and the test indicated that C390-0219 (1-10 µM) did not significantly inhibit 1 µM LPI compared 
to 1 µM LPI treatment alone. LPI (1 µM) application by itself induced robust CREB 
phosphorylation (1 µM LPI = 0.698 ± 0.173 units; Figure 3.1.6Aiii). When DMSO vehicle (1:1000) 
was applied to hGPR55-HEK293 cells, it failed to induce CREB phosphorylation (DMSO = 0.329 
Figure 3.1.5: The GPR55 antagonist C390-0219 inhibits LPI-induced increases in 
Ca2+ signal in hGPR55-HEK293 cells. (Ai-iv) Representative traces of hGPR55-HEK293 
cells treated with ligands. (Ai) A trace representing the response of one cell to 1 µM LPI 
treatment alone. (Aii) 10 µM C390-0219 did not induce Ca2+ release alone. (Aiii-iv) Cells 
were treated with C390-0219 at differing concentrations. LPI was co-perfused over the cells 
during antagonist exposure. In (iii), each differently coloured trace represents one cell. (Bi-
ii) Histograms representing changes in Ca2+ signal in cells exposed to 100nM-3 µM of C390-
0219. A paired Student’s t test was performed to compare cell treatment with C390-0219 
and 1 µM LPI, with later LPI (1 µM)-only treatment in the same population of cells. * = 
C390-0219 significantly inhibited LPI-induced increases in cellular Ca2+ signal compared to 
LPI application alone later on in the experiment (*P < 0.0157). Data is represented as mean 
± SEM. Ai-ii, iv, Bi, n =3; Aiii, n = 2; 10 µM C390-0219 (+/- LPI), n = 1. Mean peak 
response measured from 9 cells per experiment. 
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± 0.038 units; Figure 3.1.6Ai). TPA (1 µM) induced robust CREB phosphorylation (1 µM TPA = 
1.000 units; Figure 3.1.6Aii).  
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3.2.1. GPR55 stimulation with the synthetic agonist SY-020 leads to an increase in Ca2+ 
signal in the hGPR55-HEK293 cell line. 
To date, it has been extremely difficult to delineate the physiological function of GPR55 due to an 
absence of selective pharmacological tools. The development of novel GPR55 antagonists such as 
the ones used throughout this study (Heynen-genel et al., 2011; Kargl et al., 2013; Kotsikorou et al., 
2013) will help researchers to better understand the true physiological and pathological role of this 
orphan receptor. However, the selectivity of GPR55 agonists is worth scrutinising. There has been 
much debate over the classification of GPR55 as a true cannabinoid receptor or as an orphan 
receptor due to its differential responsiveness to cannabinoid and non-cannabinoid ligands in 
different cell types (Gasperi et al., 2013; Henstridge et al., 2011; Nevalainen & Irving, 2010; Sharir 
& Abood, 2010). Although LPI has been established as a potent and direct agonist of GPR55 (Oka 
et al., 2007), the selectivity of LPI for GPR55 could be contentious. For instance, LPI has 
previously been reported to signal via GPR119 in rat hepatoma cells overexpressing GPR119 (Soga 
et al., 2005), and ligands previously believed to be GPR18 agonists also signal via GPR55 (Ashton, 
2012; Ryberg et al., 2007). It is therefore important to utilise both GPR55 antagonists and GPR55-
selective agonists to determine if an experimental effect is truly GPR55-mediated. 
The effects of the synthetic GPR55 agonist SY-020 were compared with those of the endogenous 
GPR55 agonist LPI during this study. SY-020 was created by the Nevalainen research group 
(experimental work in progress). The chemical structure of SY-020 is illustrated in Figure 3.2.1A. 
Previous data has shown that hGPR55-HEK293 cells can respond to concentrations of SY-020 in 
the picomolar range. The EC50 of SY-020 in a Ca
2+ mobilisation assay was found to be 6 nM 
(Penman, experimental work in progress). 
Figure 3.1.6: The GPR55 antagonist C390-0219 attenuates LPI-induced 
CREB phosphorylation in hGPR55-HEK293 cells. (A) Phosphorylated 
CREB labelling in hGPR55-HEK 293 cells treated with (i) DMSO; (ii) 1 μM TPA 
(iii) 1 μM LPI; (iv) 10 μM C390-0219; (v) 10 μM C390-0219 + 1 μM LPI; (vi) 1 
μM C390-0219 and (vii) 1 μM C390-0219 + 1 μM LPI. (B) Histogram 
representing the effects of C390-0219 and LPI on phospho-CREB fluorescence. 
* = LPI-induced CREB phosphorylation application is statistically significant 
compared to application of 10 μM C390-0219 treatment alone (P < 0.05). Data 
is represented as mean ± SEM. Ai-v, n = 3; Avi-vii, n = 2. Fluorescence intensity 
measured from 12 cellular nuclei per experiment. Scale bar = 20 μm. 
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In this study, it was found that the application of supramaximal concentrations of SY-020 (30 nM-
100 nM) to hGPR55-HEK293 cells induced robust mobilisation of Ca2+ (hGPR55-HEK293 cells, 
30 nM SY-020 = 0.143 ± 0.014 ratio units; 100 nM SY-020 = 0.281 ratio units, n = 1; Figure 
3.2.1B). Cells produced oscillatory increases in Ca2+ signal that appeared different to the changes 
induced by LPI – the duration of the Ca2+ responses lasted substantially longer than that seen with 
LPI stimulation. Control HEK293 cells were also stimulated with SY-020 in order to determine if 
any changes in Ca2+ signal were GPR55-mediated. In Figure 3.2.1Cii, it can be observed that 
stimulation with SY-020 at concentrations below 10 μM had little or no effect on Ca2+ signal levels 
in control cells (HEK293 cells, 100 nM SY-020 = 0.058 ± 0.022 ratio units; 300 nM SY-020 = 
0.046 ± 0.002 ratio units; 1 μM SY-020 = 0.054 ± 0.015 ratio units; 3 μM SY-020 = 0.049 ± 0.015 
ratio units). However, some variable responses were observed in cells exposed to 10 μM SY-020 
(10 μM SY-020 = 0.126 ± 0.067 ratio units). An EC50 was not calculated because the response did 
not reach maximal level. It will be crucial to investigate in future if this high SY-020 concentration 
is inhibited in control HEK293 cells by the selective GPR55 antagonists utilised in this study. This 
will help to determine whether HEK293 cells may express low levels of GPR55.  
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Figure 3.2.1: The synthetic GPR55 agonist SY-020 induces increases in Ca2+ 
signal in hGPR55-HEK293 cells. (A) Chemical structure of the synthetic GPR55 
agonist SY-020. (B-Ci) Representative traces from hGPR55-HEK293 cells and 
control HEK293 cells exposed to SY-020. hGPR55-HEK293 cells were treated 
with (B) 30 nM SY-020. HEK293 cells were treated with (Ci) 10 µM SY-020. (Cii) 
Concentration-response curve representing Ca2+ release induced by SY-020 (100 
nM-10 μM) in HEK293 cells. Data is represented as mean ± SEM.  n = 3. Mean 
peak response measured from 9 cells per experiment. 
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3.2.2. The synthetic GPR55 agonist SY-020 induces CREB phosphorylation in hGPR55-
HEK293 cells but not in control HEK293 cells. 
To determine if SY-020 mediates its effects via GPR55, CREB phosphorylation was compared in 
both stably transfected HEK293 cells (hGPR55-HEK293) and in control HEK293 cells. Although 
an EC50 value has not yet been determined for SY-020 in the phospho-CREB assay in hGPR55-
HEK293 cells, preliminary findings indicated that nanomolar and micromolar (30 nM-10 µM) 
concentrations of SY-020 were capable of activating CREB. SY-020 (100 nM) seemed to 
effectively induce CREB phosphorylation so this concentration of ligand was used for the duration 
of this study (100 nM SY-020 = 1.012 ± 0.147 units; Figure 3.2.2Aii). Cells treated with DMSO 
(1:1000) did not induce pCREB activation in comparison (DMSO = 0.263 ± 0.046 units; Figure 
3.2.2Ai). Treatment with 1 µM TPA led to CREB phosphorylation (1 µM TPA = 1.000 units; data 
not shown). 
HEK293 cells were treated with 100 nM SY-020 for different lengths of time to determine whether 
time exposed to the ligand caused any variation in effect. In control HEK293 cells, 100 nM SY-
020 failed to induce CREB phosphorylation at any of the time points tested (100 nM SY-020 5 
min = 0.236 ± 0.066 units; 10 min = 0.290 ± 0.073 units; 15 min = 0.234 ± 0.122 units; 20 min = 
0.265 ± 0.092 units; 25 min = 0.186 ± 0.061 units; 30 min = 0.138 ± 0.100 units; Figure 3.2.2Av-
x). Treatment with DMSO (1:1000) did not cause CREB phosphorylation (DMSO-treated 
HEK293 cells = 0.365 ± 0.212 unit; Figure 3.2.2Aiii). CREB phosphorylation was induced in 
response to 1 µM TPA (1 µM TPA-treated HEK293 cells = 1.000 units; Figure 3.2.2Aiv). A One-
Way ANOVA was performed and determined that there was no significant difference in pCREB 
nuclear fluorescence intensities between cells exposed to SY-020 (100 nM) for different lengths of 
time of SY-020 and cells exposed to DMSO (Figure 3.2.2B). 
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3.2.3. The GPR55 antagonist D327-0013 inhibits SY-020-induced increases in Ca2+ signal 
in the hGPR55-HEK293 cell line. 
Overexpressing cells were exposed to co-applications of D327-0013 (1-10 µM) and 30 nM SY-020 
to determine if D327-0013 was capable of inhibiting SY-020-induced increases in Ca2+ signal. This 
data was compared to later application of SY-020 (30 nM) to the same populations of cells (10 µM 
D327-0013 + SY-020 30 nM = 0.039 ± 0.000 ratio units; post-washout 30 nM SY-020 = 0.081 ± 
0.006 ratio units; 52.6 ± 0% inhibition; Figure 3.2.3Aiii-iv; 3 µM D327-0013 + 30 nM SY-020 = 
0.096 ± 0.004 ratio units; post-washout 30 nM SY-020 = 0.081 ± 0.000 ratio units; 42 ± 0% 
inhibition; 1 µM D327-0013 + 30 nM SY-020 = 0.153 ± 0.060 ratio units; 37.3 ± 0.1% inhibition; 
Figure 3.2.3Aii). These experiments contrast to 30 nM SY-020 application alone in a separate 
experiment, whereby robust increases in Ca2+ signal can be observed (30 nM SY-020 alone = 0.143 
± 0.014 ratio units; Figure 3.2.3Ai). For clarity, data of cellular traces from one Ca2+ imaging 
recording has been separated into two figures; initial co-treatment with 10 µM  D327-0013 and 
SY-020 (Figure 3.2.3Aiii), and later treatment with SY-020 (Figure 3.2.3Aiv). This was to reduce 
the amount of visual noise present that would have been observed in one whole graph. A paired 
Student’s t test was performed to compare treatments of 1-10 µM D327-0013 and 30 nM SY-020 
with later treatment of SY-020 (30 nM)-only. The t test indicated that only 3 µM D327-0013 
significantly inhibited 30nM SY-020 compared to when 30 nM of SY-020 was applied after HBS 
washout in the same populations of cells (*P < 0.0451).  
Cells exposed to co-applications of 1-10 µM D327-0013 and 30 nM SY-020 were also compared 
to cells exposed to 30 nM SY-020 in separate populations of cells (30 nM SY-020 only = 0.143 ± 
0.014 ratio units; Figure 3.2.3Ai). A histogram of this data can be observed in Figure 3.2.3Biv. A 
One-Way ANOVA determined that there was no significant difference in mean peak response 
between the different treatment groups.  
Figure 3.2.2: SY-020 induces CREB phosphorylation in hGPR55-HEK293 
cells but not in control HEK293 cells. (A) Phosphorylated CREB labelling in 
hGPR55-HEK293 cells treated with (i) DMSO and (ii) 100 nM SY-020; and in 
control HEK293 cells treated with (iii) DMSO; (iv) 1 μM TPA and (v-x) 100 nM SY-
020 for 5-30 minutes. (B) Histogram representing HEK293 cell pCREB 
fluorescence intensity levels when the cells were treated with SY-020 for different 
lengths of time. n = 3. Fluorescence intensities measured from 12 cellular nuclei per 
experiment. Scale bar = 20 μm. 
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3.2.4. CREB phosphorylation induced by SY-020 is attenuated by a micromolar 
concentration of the GPR55 antagonist D327-0013 in hGPR55-HEK293 cells. 
Application of D327-0013 alone did not induce CREB phosphorylation (10 µM D327-0013 = 
0.567 ± 0.208 units; Figure 3.2.4Aiv; 3 µM D327-0013 = 0.301 ± 0.066 units; 1 µM D327-0013 = 
0.379 ± 0.223; Figure 3.2.4Avi). A concentration of 10 µM D327-0013 inhibited 100 nM SY-020-
induced CREB phosphorylation by 71.2 ± 0.1% (10 µM D327-0013 + 100 nM SY-020 = 0.259 ± 
0.056 units; Figure 3.2.4Av). No antagonism of CREB phosphorylation was observed when 1-3 
µM concentrations of D327-0013 and 100 nM SY-020 co-treatments were applied (3 µM D327-
0013 + 100 nM SY-020= 0.647 ± 0.2120 units; 28.1 ± 0.1% inhibition; 1 µM D327-0013 + 100 
nM SY-020= 0.873 ± 0.047 units; Figure 3.2.4Avii). A histogram of fluorescence intensity data 
can be observed in Figure 3.2.4B. A One-Way ANOVA was performed and determined that was 
no significant difference in fluorescence intensities between the treatment groups. Cells solely 
treated solely with 100 nM SY-020 underwent robust CREB phosphorylation (100 nM SY-020 = 
0.900 ± 0.167 units; Figure 3.2.4Aiii). DMSO (1:1000) application did not induce CREB 
phosphorylation (DMSO = 0.228 ± 0.052 units; Figure 3.2.4Ai). Stimulation with 1 µM TPA 
induced robust CREB phosphorylation (1 µM TPA = 1.000 units; Figure 3.2.4Aii).  
Figure 3.2.3: D327-0013 GPR55 antagonist inhibits SY-020-induced increases 
in Ca2+ signal in hGPR55-HEK293 cells. (Ai-iv) Representative traces recorded 
from hGPR55-HEK293 cells treated with ligands. (Ai) Traces of recorded cell data 
showing increases in Ca2+ signal induced by 30 nM of SY-020 alone. (Aii) Traces of 
recorded cell data exposed to 1 µM D327-0013 and 30 nM SY-020. (Aiii) Traces of 
recorded cell data exposed to 10 µM D327-0013 and SY-020, and (Aiv) later SY-
020 (30 nM) treatment following HBS washout. (Bi-iv) Histograms representing the 
effects on Ca2+ signal when cells were exposed to 1-10 µM of D327-0013. Paired t 
tests were performed to compare the effects of 1-10 µM D327-0013 and 30 nM 
SY-020, with 30 nM SY-020 when it was applied later on to the same populations 
of cells. * = 3 µM D327-0013 significantly inhibits SY-020-induced increases in 
Ca2+ signal compared to later 30 nM SY-020 treatment alone (*P < 0.0451). Data 
is represented as mean ± SEM. Ai-Aii, n = 3; Aiii-iv, n =2. Mean peak response 
measured from 9 cells per experiment. 
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3.2.5. The GPR55 antagonist C390-0219 attenuates SY-020-induced increases in Ca2+ signal 
in the hGPR55-HEK293 cell line. 
Overexpressing cells were exposed to co-applications of C390-0219 (1 and 10 µM) and 30 nM SY-
020 to determine if C390-0219 was capable of inhibiting SY-020-induced increases in Ca2+ signal 
(Figure 3.2.5Aii-iv). This data was compared to later application of SY-020 (30 nM) alone later on 
in the same populations of cells (10 µM C390-0219 + SY-020 30 nM = 0.124 ± 0.001 ratio units; 
post-washout 30 nM SY-020 = 0.496 ± 0.186 ratio units; 75.0 ± 0% inhibition; Figure 3.2.5Aiii-
iv; 1 µM C390-0219 + 30 nM SY-020 = 0.070 ± 0.261 ratio units; Figure 3.2.3Aii). These 
experiments contrast to 30 nM SY-020 application alone in a separate experiment, whereby robust 
increases in Ca2+ signal can be observed (30 nM SY-020 alone = 0.143 ± 0.014 ratio units; Figure 
3.2.5Ai). For clarity, data of cellular traces from one Ca2+ imaging recording has been separated 
into two figures; initial co-treatment with 10 µM C390-0219 and SY-020 (Figure 3.2.5Aiii), and 
later treatment with SY-020 (Figure 3.2.5Aiv). This was to reduce the amount of visual noise 
present that would have been observed in one whole graph. A paired Student’s t test was 
performed to compare treatments of 10 µM C390-0219 and 30 nM SY-020 with later treatment of 
SY-020 (30 nM)-only (Figure 3.2.5Bii). The t test that determined that 10 µM C390-0219 did not 
significantly inhibit 30 nM SY-020 (P < 0.2240). A paired t test could not be performed on cellular 
data obtained from cells exposed to 1 µM C390-0219 and 30 nM SY-020 because only an n =1 
was obtained (Figure 3.2.5Aii, Bi). However, one can see from Figure 3.2.5Aii-iv and Bi-ii that 
there appears to be attenuative effects of C390-0219 (1 µM and 10 µM) on SY-020-induced 
increases in Ca2+ signal.  
Cells exposed to co-applications of 10 µM C390-0219 and 30 nM SY-020 were also compared to 
cells exposed to just 30 nM SY-020 in separate populations of cells (30 nM SY-020 only = 0.143 
Figure 3.2.4: The GPR55 antagonist D327-0013 attenuates SY-020-induced CREB 
phosphorylation in hGPR55-HEK293 cells. (A) Phosphorylated CREB labelling in 
hGPR55-HEK 293 cells treated with (i) DMSO; (ii) 1 μM TPA (iii) 100 nM SY-020; (iv) 
10 μM D327-0013; (v) 10 μM D327-0013 + 100 nM SY-020; (vi) 1 μM D327-0013 and (vii) 
1 μM D327-0013 + 100 nM SY-020. (B) Histogram representing the effects of D327-0013 
and SY-020 on phospho-CREB fluorescence. Data is represented as mean ± SEM. n =2. 
Fluorescence intensity measured from 12 cellular nuclei per experiment. Scale bar = 20 
μm. 
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± 0.014 ratio units; Figure 3.2.3Ai). A histogram of this data can be observed in Figure 3.2.3Biii. 
A Mann-Whitney U test determined that 10 µM C390-0219 did not have a significant inhibitory 
effect on SY-020 (30nM)-induced increases in Ca2+ signal. 
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3.2.6. CREB phosphorylation induced by SY-020 is attenuated by the GPR55 antagonist 
C390-0219 in hGPR55-HEK293 cells. 
Application of C390-0219 alone did not induce CREB phosphorylation (10 µM C390-0219 = 
0.302 ± 0.037 units; 3 µM C390-0219 = 0.321 ± 0.060 units; 1 µM C390-0219 = 0.377 ± 0.099 
units; Figure 3.2.6Aiv, vi). Treatment with 10 µM C390-0219 and 100 nM SY-020 led to inhibition 
of pCREB by 49.8 ± 0.3% (10 µM C390-0219 + 100 nM SY-020 = 0.507 ± 0.295 units; Figure 
3.2.6Av). A concentration of 3 µM C390-0219 + 100 nM SY-020 did not antagonise SY-020-
induced CREB phosphorylation (3 µM C390-0219 + 100 nM SY-020 = 1.112 ± 0.831 units). 
However, a concentration of 1 µM C390-0219 appeared to antagonise 100 nM SY-020 more-so 
than 10 µM C390-0219 (1 µM C390-0219 + 100 nM SY-020 = 0.343 ± 0.084 units; 66 ± 0.1% 
inhibition; n = 2; Figure 3.2.6 Avii). There was variability in the data obtained for 10 µM C390-
0219 and 100 nM SY-020 treatment however, so this may be why 10 µM of C390-0219 appeared 
to be less effective at inhibiting 100 nM of SY-020.  
A histogram of fluorescence intensity data can be observed in Figure 3.2.6B. A One-Way ANOVA 
was performed to determine if there was a significant difference in fluorescence intensities when 
cells were treated with 1-10 µM C390-0219 and 100 nM SY-020. The One-Way ANOVA 
confirmed that there was a significant difference in fluorescence intensities between the groups 
but Bonferroni’s Post hoc test did not detect a significant effect of C390-0219-mediated inhibition 
on SY-020-induced CREB phosphorylation. SY-020 (100 nM) treatment alone induced robust 
CREB phosphorylation (100 nM SY-020 = 1.012 ± 0.147 units; Figure 3.2.6Aiii). DMSO (1:1000) 
Figure 3.2.5: The GPR55 antagonist C390-0219 attenuates SY-020-induced 
increases in Ca2+ signal in hGPR55-HEK293 cells. (Ai-iv) Representative traces 
recorded from hGPR55-HEK293 cells treated with ligands. (Ai) Traces of recorded 
data showing cellular increases in Ca2+ signal induced by 30 nM of SY-020 alone. 
(Aii) Traces of recorded data when cells were exposed to 1 µM C390-0219 and 30 
nM SY-020. (Aiii) Traces of recorded data when cells were exposed to 10 µM C390-
0219 and 30 nM SY-020, and (Aiv) later SY-020 (30 nM) treatment following HBS 
washout. (Bi-iv) Histograms representing the effects on Ca2+ signal when cells were 
exposed to 1 and 10 µM of C390-0219. Paired t tests were performed to compare 
the effects induced by 10 µM C390-0219 and 30 nM SY-020, with the effects 
induced by 30 nM SY-020 when it was applied later on to the same populations of 
cells. Data is represented as mean ± SEM. Ai, Aiii-iv n = 3; Aii, n = 1. Mean peak 
response measured from 9 cells per experiment.  
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application did not induce CREB phosphorylation (DMSO = 0.433 ± 0.207 units; Figure 3.2.6Ai). 
Stimulation with 1 µM TPA induced robust CREB phosphorylation (1 µM TPA = 1.000 units; 
Figure 3.2.6Aii).  
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3.3.1. LPI stimulation leads to an increase Ca2+ signal in the DU145 prostate cancer cell 
line. 
In the DU145 prostate cancer cell line, perfusion with a supramaximal concentration of LPI (3 
µM) induced an increase in Ca2+ signal (3 µM LPI = 0.326 ± 0.157 ratio units; Figure 3.3.1A). This 
corroborates with previous data, whereby 3 µM LPI was sufficient to induce increases in Ca2+ 
signal in DU145 cells (Penman, 2013). In vitro models that express GPR55 endogenously e.g. 
DU145 prostate cancer cells, need higher concentrations of agonist to stimulate the receptor 
because GPR55 is not expressed as highly in native cells as it is in recombinant systems (Piñeiro et 
al., 2011).  
Please note that at the beginning of this research project, DU145 cells originally obtained from the 
Division of Cancer Research at the University of Dundee were used for experiments. However, 
further into the project this batch of cells became unresponsive to LPI. A new batch of DU145 
cells obtained from the Centre for Diabetes at the Queen Mary University of London was used 
for the remainder of the project.  
 
 
 
 
 
Figure 3.2.6: C390-0219 GPR55 antagonist attenuate SY-020-induced CREB 
phosphorylation in hGPR55-HEK293 cells. (A) Phosphorylated CREB labelling in 
hGPR55-HEK293 cells treated with (i) DMSO; (ii) 1 μM TPA (iii) 100 nM SY-020; (iv) 10 
μM C390-0219; (v) 10 μM C390-0219 + 100 nM SY-020; (vi) 1 μM C390-0219 and (vii) 1 μM 
C390-0219 + 100 nM SY-020. (Bi-ii) Histograms representing the effects of C390-0219 and 
SY-020 on phospho-CREB fluorescence. A One-Way ANOVA was performed to analyse 
the significance of C390-0219 effectiveness in inhibiting SY-020-induced CREB 
phosphorylation. Data is represented as mean ± SEM. Ai-v, Bi, n =3; Avi-ii, Bii, n = 2. 
Fluorescence intensity measured from 12 cellular nuclei per experiment. Scale bar = 20 μm. 
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3.3.2. LPI stimulation leads to the phosphorylation of CREB in the DU145 prostate cancer 
cell line. 
CREB phosphorylation was investigated in DU145 prostate cancer cells because receptor 
stimulation and protein kinase-dependent signalling mechanisms induce the activation of CREB 
in these cells. Interestingly, CREB phosphorylation has been linked to tumorigenicity and prostate 
cancer cell progression (Park et al., 2013).  It was therefore of interest to see if GPR55 stimulation 
with LPI could induce CREB phosphorylation. 
Cells treated with 1 µM LPI exhibited evidence of substantial CREB phosphorylation which was 
localised to the cell nucleus (1 µM LPI = 0.614 ± 0.081 units; Figure 3.3.2Aiii). This corroborates 
with previous data, whereby 1 µM LPI was sufficient to induce CREB phosphorylation in DU145 
cells (Penman, 2013). A Mann-Whitney U test determined that there was no significant difference 
in pCREB fluorescence between cells treated with 1 µM LPI and those treated with DMSO (P < 
0.1000; Figure 3.3.2B). Cells treated with DMSO (1:1000) for 25 minutes failed to show signs of 
CREB phosphorylation (DMSO = 0.241 ± 0.028 units; Figure 3.3.2Ai). In Figure 3.3.2Aii, 
LPI 3 M
0.
2 
u
n
it
s
5 min
Figure 3.3.1: LPI induces increases in Ca2+ signal in DU145 prostate cancer 
cells. Traces from two DU145 cells representing an increase in fluorescence ratio 
signal when the cells were exposed to 3 µM LPI. n = 3. 
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treatment of the cells with 1 µM TPA for 25 minutes resulted in a substantial increase in the 
phosphorylation of CREB (1 µM TPA = 1.000 units).  
 
 
 
 
 
 
 
3.3.3. The GPR55 antagonist D327-0013 fails to inhibit LPI-induced increases in Ca2+ 
signal in the DU145 prostate cancer cell line. 
Not all of the experimental groups obtained for treatment with 10 μM D327-0013 and 3 μM LPI 
were exposed to later application with 3 μM of LPI following a washout with HBS. For this reason, 
an unpaired and two-tailed Mann-Whitney U test was performed to compare groups treated with 
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Figure 3.3.2: LPI induces CREB phosphorylation in DU145 cells. (A) 
Phosphorylated CREB labelling in DU145 cells treated with (i) DMSO; (ii) 1 μM TPA 
and (iii) 1 µM LPI. (B) A histrogram representing the effects of ligand treatments on 
pCREB fluorescence levels. Ai-iii, B, n = 3. Fluorescence intensities measured from 
12 cellular nuclei per experiment. Scale bar = 20 μm. 
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10 μM D327-0013 and 3 μM LPI with treatment groups exposed to 3 μM of LPI in separate 
populations of cells. The U test showed that 10 μM D327-0013 did not inhibit LPI (3 μM)-induced 
increases in Ca2+ signal (10 μM D327-0013 + 3 μM LPI = 0.322 ± 0.038 ratio units; P < 0.7000; 
Figure 3.3.3A-B) compared to LPI (3 μM) application alone (0.326 ± 0.157 ratio units; Figure 
3.3.3B).  
Due to time constraints, cells were not treated with D327-0013 alone. In future it will be pertinent 
to treat cells with D327-0013 to observe if the ligand itself induces increases in fluorescence ratio 
signal, which would indicate the release of Ca2+ from intracellular stores. 
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Figure 3.3.3: The GPR55 antagonist D327-0013 fails to inhibit LPI-induced 
increases in Ca2+ signal in DU145 cells. (A) Representative traces from DU145 
cells treated with ligands. Cells were exposed to 10 μM D327-0013 and LPI (3 μM) 
was co-perfused over the cells during antagonist exposure. (B) Histogram 
representing differences in mean peak response between treatment groups. Data is 
represented as mean ± SEM. n = 3. Mean peak response measured from 9 cells 
per experiment. Some data produced by June Penman. 
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3.3.4. The GPR55 antagonist C390-0219 fails to inhibit LPI-induced increases in Ca2+ 
signal in the DU145 prostate cancer cell line. 
Not all of the experimental groups obtained for treatment with 10 μM C390-0219 and 3 μM LPI 
were exposed to later application with 3 μM of LPI following a washout with HBS. For this reason, 
an unpaired and two-tailed Mann-Whitney U test was performed to compare groups treated with 
10 μM C390-0219 and 3 μM LPI with treatment groups exposed to 3 μM of LPI in separate 
populations of cells. The U test showed that 10 μM C390-0219 did not significantly attenuate 
increases in Ca2+ signal induced by LPI (3 μM), with a percentage of inhibition of 22.5 ± 0.1% (10 
μM C390-0219 + 3 μM LPI = 0.253 ± 0.140 ratio units, (P < 0.7000)); Figure 3.3.4A) compared 
to LPI (3 μM) application alone (0.326 ± 0.157 ratio units) (Figure 3.3.4A-B). However, there was 
a large degree of variability in both treatment groups, which could have affected the U test result.  
Due to time constraints, cells were not treated with C390-0219 alone. In future it will be pertinent 
to treat cells with C390-0219 to observe if the ligand itself causes an increase in Ca2+ signal.  
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3.4.1. The synthetic GPR55 agonist SY-020 fails to induce increases in Ca2+ signal in the 
DU145 prostate cancer cell line. 
DU145 cells were stimulated with SY-020 in order to determine if changes in the Ca2+ signal were 
induced via a GPR55-mediated mechanism. An initial concentration of 300 nM SY-020 was 
chosen because this concentration causes potent increases in fluorescence ratio signal in hGPR55-
HEK293 cells. Although endogenous GPR55 expression produces less potent Ca2+ responses than 
overexpressing cells – as discussed previously – we believed that 300 nM SY-020 was a suitable 
starting concentration. SY-020 (300 nM) did not lead to increases in the fluorescence ratio signal 
(300 nM SY-020 = 0.103 ± 0.033 ratio units; n = 2; Figure 3.4.1A). This suggests that GPR55 does 
not mediate intracellular Ca2+ release in the DU145 prostate cancer cell line, which is in contrast 
with previous data (Piñeiro et al., 2011).  
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Figure 3.3.4: The GPR55 antagonist C390-0219 fails to inhibit LPI-induced 
increases in Ca2+ signal in DU145 cells. (A-C) Representative traces from 
DU145 cells treated with ligands. These cells were exposed to 100 nM-1 μM, and 
10 μM C390-0219. LPI was co-perfused over the cells during antagonist exposure. 
(B) Histogram representing differences in mean peak response between treatment 
groups. Data is represented as mean ± SEM. A, n = 3, B-C, n =1. Mean peak 
response measured from 9 cells per experiment. Some data produced by June 
Penman. 
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3.4.2. SY-020 induces CREB phosphorylation in the DU145 cell line. 
DU145 cells were exposed to increasing concentrations of SY-020 ligand (10 nM-1 μM). A 
representative image of cells stimulated with 30 nM of SY-020 can be observed in Figure 3.4.2C 
(10 nM SY-020 = 1.323 ± 0.595 units; 30 nM SY-020 = 0.444 ± 0.111 units; 100 nM SY-020 = 
1.517 ± 1.059 units; 300 nM SY-020 = 0.106 ± 0.073 units; 1 µM SY-020 = 0.207 ± 0.134 units). 
Control cells treated with vehicle DMSO (1:1000) showed low levels of CREB phosphorylation 
(DMSO = 0.721 ± 0.570 units; Figure 3.4.2A), but there was variability in pCREB nuclear 
fluorescence amongst the experimental groups which altered the fluorescence intensity data. When 
the cells were treated with 1 µM TPA it induced CREB phosphorylation (1 µM TPA = 1.000 units; 
Figure 3.4.2B).  
There were issues in obtaining a concentration-response curve due to variability within the raw 
data obtained. For instance, pCREB nuclear fluorescence was quite low for TPA-treated cells in 
one experimental group and this affected the normalised result of that group.  Perhaps repeating 
this assay will aid in decreasing variability.  
 
  
 
 
DMSO TPA 1 μM SY-020 30 nM
A B C
Figure 3.4.1: The synthetic GPR55 agonist SY-020 fails to induce Ca2+ signal 
increases in DU145 cells. A representative trace from a DU145 cell treated with 
(A) 300 nM SY-020. n = 2. Mean peak response measured from 9 cells per 
experiment. 
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3.5.1. LPI has neuroprotective effects against β-amyloid in cortical neurons.  
GPR55 mRNA expression has been identified in various regions of the brain e.g. frontal cortex, 
hypothalamus, striatum, amygdala and cerebellar granule cells (Chiba et al., 2011; Kerr et al., 2013; 
Ryberg et al., 2007; Sawzdargo et al., 1999) and the regulatory effects of GPR55 have been 
implicated in the modulation of synaptic transmission (Sylantyev et al., 2011, 2013) and in 
neuroimmune function, as GPR55 mRNA is expressed in microglia (Pietr et al., 2009). There is 
increasing interest in the role of GPR55 in neurodegenerative mechanisms however. Cannabinoids 
e.g. Δ9-THC and 2-AG, have previously been shown to mediate neuroprotective effects in models 
of neuronal degeneration (Campbell, 2001; Downer et al., 2007; Gowran et al., 2011; Noonan et al., 
2010), and the putative GPR55 agonist O-1602 was shown to reduce the formation of aggregated 
β-amyloid fibrils and reduce the activation of the microglial BV-2 cell line in response to 
lipopolysaccharide (LPS) in an in vitro model of AD. It was therefore of interest to investigate if 
GPR55 had regulatory effects in degenerating primary cortical neurons exposed to Aβ. 
Fixed cortical neurons were stained for caspase-3, NeuN and Hoechst. The neurons were stained 
for caspase-3 because the analysis of this stain can help to determine if the neurons are undergoing 
apoptosis or not (Figure 3.5.1Ai, Bi-iv) (Campbell, 2001; Jänicke et al., 1998). The neurons were 
stained for NeuN because this antibody recognises the protein NeuN which is present in most of 
the neuronal cell types of vertebrates (Figure 3.5.1Aii) (Wolf et al., 1996). This helped to distinguish 
cortical neurons from other remaining non-neuronal cells that were present in the culture upon 
fixation. For instance, in Figure 3.5.1Aii, the blue arrow denotes a glial cell because the NeuN 
antibody has not stained that cell particularly well compared to the other cells. The shape of the 
glial cell is rounder and different from that of the surrounding neuronal cells. Hoechst stain was 
used in order to detect cellular DNA and nuclei (Figure 3.5.1Aiii) (Latt et al., 1975; Latt & Stetten, 
1976). All three stains were visualised using a confocal microscope. The wavelength channels from 
the images taken were combined in order to create a “merged” image (Figure 3.5.1Aiv). 
Representative images of caspase-3 activity can be observed in Figure 3.5.1Bi-iv. Upon qualitative 
analysis, it was observed that neurons looked far less healthy when exposed to amyloid-beta (Aβ) 
Figure 3.4.2: SY-020 induces CREB phosphorylation in DU145 cells. 
Phosphorylated CREB labelling in DU145 cells treated with (A) DMSO; (B) 1 μM 
TPA and (C) 30 nM SY-020. Data presented as mean ± SEM. n = 3. Fluorescence 
intensity values obtained from 12 cellular nuclei per experiment. Data produced 
by Cullen McCulloch. Scale bar = 20 μm. 
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(1 µM Aβ = 1781.53 ± 331.28 units; Figure 3.5.1Bii) compared to when they were treated only 
with normal medium (Control = 995.36 ± 111.25 units; Figure 3.5.1Bi; control). Aβ-treated 
neurons were shrunken in appearance, possessed distorted and retracted projections and were 
visibly brighter in fluorescence. When cortical neurons were exposed to LPI in the presence or 
absence of Aβ however, neuronal fluorescence appeared darker and the condition of the neurons 
was comparable to that of control neurons (10 µM LPI = 1026.82 ± 233.70 units; 10 µM LPI + 1 
µM Aβ = 1137.81 ± 283.60 units; Figure 3.5.1Biii-iv). This suggests that LPI has a protective effect 
when neurons are exposed to neurotoxic Aβ. A One-Way ANOVA was performed on this data 
and determined that there was no significant difference in capase-3 fluorescence between each 
treatment group. 
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3.5.2. The GPR55 antagonist D327-0013 does not inhibit the neuroprotective effects of LPI 
in cortical neurons exposed to β-amyloid. 
D327-0013 (3 μM) did not induce any observable changes to caspase-3 activity in cortical neurons 
when applied alone (3 μM D327-0013 = 712.58 ± 341.17 units; Figure 3.5.2Av) but the 
fluorescence appeared brighter when the cells were co-treated with Aβ (3 μM D327-0013 + 1 μM 
Aβ = 1287.76 ± 111.43 units; Figure 3.5.2Avi). This suggests that D327-0013 was not capable of 
protecting cortical neurons against neurotoxic Aβ when applied alone. Fluorescence intensity 
levels of the apoptotic marker, caspase-3, can be observed in Figure 3.5.2B. A One-Way ANOVA 
was performed to detect any differences in caspase-3 fluorescence intensities between the 
treatment groups. The ANOVA indicated that there was no significant difference between the 
groups. It can be observed from the graph that neurons treated with 3 µM D327-0013 and 10 µM 
LPI in the presence or absence of Aβ had fluorescence intensity values and a similar appearance 
to control neurons (3 μM D327-0013 + 10 µM LPI = 1187.206 units; 3 μM D327-0013, 10 µM 
LPI + 1 μM Aβ = 1320.63 units; Figure 3.5.2Avii-viii). They did not appear shrunken and distorted 
like neurons treated with just Aβ alone. This suggests that 3 µM D327-0013 was ineffective at 
inhibiting the seemingly neuroprotective effects of 10 μM LPI in the presence of Aβ (Jänicke et al., 
1998). However, these latter treatments only consisted of one experimental group each. A 
concentration of 3 μM D327-0013 was used in these preliminary experiments in consideration of 
the data obtained using the other in vitro models in this study. This data suggested that a 
concentration range of 3-10 μM of antagonist inhibited a working concentration of GPR55 agonist.  
Figure 3.5.1: LPI has neuroprotective effects against β-amyloid. (A) 
Representative images of cortical neurons stained for (i) caspase-3; (ii) NeuN; (iii) 
Hoechst and (iv) a combination of all three stains. (B) Representative images of 
caspase-3 activity in cortical neurons exposed to (i) normal medium (control); (ii) 1 
µM Aβ; (iii) 10 µM LPI; and (iv) 10 µM LPI in the presence of 1 µM Aβ. Non-
neuronal cells (glia) are denoted by the blue arrow. n = 2. Fluorescence intensities 
measured from 7 cellular bodies per experiment. Scale bar = 20µm.  
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3.5.3. The GPR55 antagonist C390-0219 attenuates the neuroprotective effects of LPI in 
cortical neurons exposed to β-amyloid. 
C390-0219 did not induce any observable changes to caspase-3 activity in the neurons when applied 
alone (3 µM C390-0219 = 1351.07 ± 160.83 units; Figure 3.5.3Av) but the fluorescence appeared 
brighter when the cells were co-treated with Aβ (3 µM C390-0219 + 1 µM Aβ = 1934.62 units; n =1; 
Figure 3.5.3Avi). This suggests that C390-0219 was not capable of protecting cortical neurons against 
neurotoxic Aβ when applied alone. Fluorescence intensity levels of the apoptotic marker, caspase-3, 
can be observed in Figure 3.5.3B. A One-Way ANOVA was performed to detect any differences in 
caspase-3 fluorescence intensities between the treatment groups. The ANOVA indicated that there 
was no significant difference between the groups. It can be observed from the graph that neurons 
treated with 3 µM C390-0219 and 10 µM LPI in the presence or absence of Aβ differed in fluorescence 
intensity (3 µM C390-0219 +10 µM LPI = 735.70 ± 6.58 units; 3 µM C390-0219, 10 µM LPI + 1 µM 
Aβ = 1126.64 ± 16.6 units). This suggests that 3 µM C390-0219 was somewhat effective at inhibiting 
the seemingly neuroprotective effects of 10 μM LPI in the presence of Aβ. (Figure 3.5.3Avii-viii). 
Figure 3.5.2: D327-0013 does not inhibit the potential neuroprotective effects of 
LPI in cortical neurons. (A) Representative images of caspase-3 activity in cortical 
neurons exposed to (i) normal medium (control); (ii) 1 µM Aβ; (iii) 10 µM LPI; (iv) 10 
µM LPI and 1 µM Aβ; (v) 3 µM D327-0013; (vi) 3 µM D327-0013 and 1 µM Aβ; (vii) 3 
µM D327-0013 and 10 µM LPI and (viii) 3 µM D327-0013, 10 µM LPI and 1 µM Aβ. (B) 
Histogram representing the effects of D327-0013, LPI and Aβ on caspase-3 fluorescence 
intensity. Data is represented as mean ± SEM. All groups, n = 2, except 3 µM D327-
0013 and 10 µM LPI; and 3 µM D327-0013, 10 µM LPI and 1 µM Aβ, n = 1. Fluorescence 
intensities measured from 7 individual neuronal cell bodies per treatment group per 
experiment. Scale bar = 20µm.  
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Figure 3.4.3: C390-0219 attenuates the potential neuroprotective effects of LPI in 
cortical neurons. (A) Representative images of caspase-3 activity in cortical neurons 
exposed to (i) normal medium (control); (ii) 1 µM Aβ; (iii) 10 µM LPI; (iv) 10 µM LPI 
and 1 µM Aβ; (v) 3 µM C390-0219; (vi) 3 µM C390-0219and 1 µM Aβ; (vii) 3 µM C390-
0219 and 10 µM LPI and (viii) 3 µM C390-0219, 10 µM LPI and 1 µM Aβ. (B) Histogram 
representing the effects of C390-0219, LPI and Aβ on caspase-3 fluorescence intensity. 
Data is represented as mean ± SEM. All groups, n = 2, except 3 µM C390-0219 and 1 
µM Aβ, n = 1. Fluorescence intensities measured from 7 individual neuronal cell bodies 
per treatment group per experiment. 
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4.1. Inhibition of GPR55-mediated signalling using selective antagonists 
To date it has been extremely difficult to delineate the physiological and pathological roles of 
GPR55 due to a lack of selective pharmacological tools. The data presented herein demonstrates 
that two novel and selective GPR55 antagonists are capable of inhibiting agonist-induced 
responses at a concentration of 3 µM in a HEK293 cell line stably transfected with GPR55 
(hGPR55-HEK293). Previous studies have provided evidence which supports certain 
cannabinoids acting as antagonists at GPR55. The cannabinoid CP55,940 inhibits GPR55 
internalization, the formation of β-arrestin GPR55 complexes and the phosphorylation of ERK 
(Kapur et al., 2009). The CB1 inverse agonist/antagonist SR141716A was previously described as 
an antagonist of GPR55 when it inhibited the effects of GPR55 agonists in hGPR55-HEK293 
cells (Lauckner et al., 2008), but it has since been identified as a GPR55 agonist along with the 
structurally similar cannabinoid AM251 (Henstridge et al., 2010; Kapur et al., 2009). The 
phytocannabinoid cannabidiol was suggested to antagonise GPR55-mediated GTPγS binding 
(Ryberg et al., 2007). The CBD analogue O-1918 is also a proposed GPR55 antagonist and has 
been shown to inhibit the therapeutic effects of the putative GPR55 agonist O-1602 in a rat model 
of acute arthritis (Schuelert & McDougall, 2011) and inhibit the attenuating effects of O-1602 on 
mesenchymal stem cell migration (Schmuhl et al., 2014). The issue with previously reported 
antagonists however is their lack of selectivity for GPR55 in certain cell types and physiological 
conditions. The coumarin derivatives PSB-SB-487 and PSB-SB-1203 were found to be potent and 
selective antagonists however (Rempel et al., 2013). The data described in the current study is 
therefore very encouraging because it further characterises two effective and selective antagonists 
for GPR55.  
Both D327-0013 and C390-0219 did not induce any effects in hGPR55-HEK293 cells when 
applied alone. They both significantly inhibited LPI-induced Ca2+ responses when applied at a 
concentration of 3 μM in hGPR55-HEK293 cells, but only D327-0013 (3 μM) significantly 
inhibited SY-020-induced increases in Ca2+ signal in these cells. Agonist-induced Ca2+ responses 
were inhibited more effectively by the antagonists than pCREB activation responses. Perhaps the 
antagonists exhibit ligand bias towards signalling pathways that lead to Ca2+ release more-so than 
CREB phosphorylation signalling pathways in hGPR55-HEK293 cells. Neither antagonist was 
capable of inhibiting LPI-induced Ca2+ release in DU145 cells, but preliminary data indicates that 
3-10 μM of both antagonists inhibit 1 μM of LPI-induced CREB phosphorylation (Penman, 
experimental work in progress). However, a control experiment of antagonist treatment alone was 
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not performed. In future it will be crucial to treat cells with the antagonists to ensure the 
antagonists are not inducing Ca2+ responses themselves in DU145 prostate cancer cells.  
Ca2+ release from intracellular stores can be induced in DU145 cells using suggested LPI-mediated 
stimulation of GPR55 (Penman, 2013; Piñeiro et al., 2011). Interestingly, although the specific 
ROCK inhibitor Y-27632 strongly inhibited LPI-dependent ERK phosphorylation in DU145 cells, 
it was previously shown not to affect LPI-dependent Ca2+ release (Piñeiro et al., 2011). The authors 
therefore theorised that LPI is capable of inducing increased levels of intracellular Ca2+ in a 
GPR55-dependent mechanism but independently of ROCK involvement. In contrast, hGPR55-
HEK293 cells have previously been shown to induce GPR55-mediated Ca2+ release via a Gα13-
RhoA-ROCK pathway (Henstridge et al., 2009a). Prostate cancer cells express GPCRs such as 
GPR55 (Piñeiro et al., 2011; Raj et al., 2002) and DU145 cells are theorised to signal via a GPR55-
Gαq protein mechanism which induces the Rho-mediated downstream activation of ERK 
(Penman, 2013; Piñeiro et al., 2011). ERK is vital in prostate cancer cell proliferation and advanced 
prostate tumours express elevated levels of activated ERK (Gioeli et al., 1999; Price et al., 1999).  
The data presented herein conflicts with the findings made by Piñeiro et al. (2011). It has previously 
been shown that GPR55-mediated Ca2+ release is induced via a ROCK-independent mechanism 
in DU145 cells (Penman, 2013), which corroborates with the data obtained by Piñeiro et al. (2011). 
However, the current data suggests that in the DU145 prostate cancer cell line, GPR55 does not 
mediate the release of Ca2+ from intracellular stores. Perhaps DU145 cells do not mediate the 
release of Ca2+ through Gαq-coupling, which conflicts with previous findings (Piñeiro et al., 2011; 
Piñeiro & Falasca, 2012; Ruban et al., 2014). Piñeiro et al. (2011) also transfected GPR55 siRNA 
into another prostate cancer cell line (PC-3 cells) which led to subsequent downregulation of 
GPR55 expression and prevention of LPI-induced Ca2+ release. Only pharmacological tools, i.e. 
antagonists, were used to validate GPR55-mediated mechanisms in this study. Future work should 
therefore aim to implement alternative methods, such as the use of siRNA for GPR55, in order to 
confirm ligand selectivity for GPR55.  
It is worth noting that when Gα13-coupled GPR55 is stimulated by an agonist in hGPR55-HEK293 
cells, PLCε is activated downstream and cleaves PIP2 into IP3. IP3 subsequently binds to IP3Rs on 
the ER membrane which induces the release of Ca2+ from the ER stores. DU145 prostate cancer 
cells express PLCβ, so the findings presented herein may suggest that GPR55 only mediates the 
release of intracellular Ca2+ when PLCε is expressed by cells. A diagram representing the potential 
signalling pathways induced by LPI in DU145 cells is illustrated in Figure 4.1. 
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Figure 4.1. Potential signalling cascades and effects induced by LPI in DU145 prostate cancer cells. 
Upon activation of GPR55 by LPI, Gαq protein is activated. The signal transduced leads to phosphorylation 
of CREB. pCREB translocates to the cell nucleus and induces gene transcription. This gene expression is 
suggested to contribute to cancer cell proliferation and metastasis. GPR55 antagonists are capable of 
inhibiting this pathway at the receptor level (Penman, 2013), thus preventing LPI from inducing 
downstream CREB phosphorylation. However, LPI appears to activate an as yet unknown target in order 
to induce the release of Ca2+ in DU145 cells. This target is not inhibited by GPR55 antagonists. The red 
dashed arrows indicate a suggested pathway for LPI-mediated Ca2+ mobilisation in DU145 cells. 
 
4.2. Selective agonism for GPR55 
The selectivity of agonists for GPR55 has long come under scrutiny since the receptor was first 
identified by Sawzdargo et al. (1999). Previous studies proposed that GPR55 could be activated by 
cannabinoid ligands. Ryberg et al. (2007) showed that GPR55 was activated by cannabinoids e.g. 
CP55,940, Δ9-THC, AEA, 2-AG, PEA, virodhamine and others, in a GTPγS binding assay. 
However, other studies have provided contrasting evidence which only replicates some of the data 
produced by Ryberg et al. (2007) (Johns et al., 2007) or does not replicate the data at all (Oka et al., 
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2007). Furthermore, studies in recent years have provided increasing amounts of evidence 
identifying LPI as the endogenous agonist for GPR55 (Nevalainen & Irving, 2010; Oka et al., 2007; 
Piñeiro & Falasca, 2012; Yamashita et al., 2013). The discrepancies surrounding endogenous 
agonist selectivity for GPR55 have only made the need for selective agonists all the more vital. To 
date, very few selective agonists have been synthesised. Heynen-Genel et al. (2011) identified 
several potent and selective agonists for GPR55. The agonists ML184 (2440433), ML185 
(CID1374043) and ML186 (CID15945391) were ranked in the order ML185 >ML198 >ML184 
in terms of potency. Brown et al. (2011) identified the benzoylpiperazines, GSK494581A and 
GSK575594A, as GPR55 agonists, which were initially thought to be inhibitors of glycine 
transporter subtype 1 (GlyT1).  However, these agonists were only selective for human GPR55 
and not rodent GPR55. This could present problems when trying to delineate the physiological 
role of GPR55 in in vitro and in vivo models.  
The data presented herein demonstrates that a novel and selective agonist for GPR55, SY-020, is 
capable of mediating GPR55-specfic effects in the hGPR55-HEK293 and DU145 prostate cancer 
cell lines. It did not induce GPR55-specific effects in the control HEK293 cell line in comparison, 
except for 10 µM SY-020. It would be worth testing this high SY-020 concentration with the 
antagonists used in this study to clarify if the increases in Ca2+ signal were wholly GPR55-mediated 
in these control cells. SY-020 was synthesised by the Nevalainen research group. Previous data 
showed that in a Ca+ imaging assay, SY-020 had an EC50 = 6 nM in hGPR55-HEK293 cells 
(Penman, 2013). This was confirmed by the findings presented in the current study, whereby a 
concentration of SY-020 (30 nM) was capable of inducing increases in Ca2+ signal. Although both 
antagonists attenuated SY-020-induced increases in Ca2+ release, only D327-0013 (3 μM) 
significantly inhibited this Ca2+ release. This suggests that GPR55 mediated this release of Ca2+ 
from intracellular stores. SY-020 was also capable of inducing the GPR55-mediated 
phosphorylation of CREB in hGPR55-HEK293 cells, and the GPR55 antagonists D327-0013 and 
C390-0219 both attenuated levels of pCREB fluorescence.  
Interestingly, although SY-020 did induce CREB phosphorylation in the DU145 prostate cancer 
cell line, 300 nM of SY-020 did not induce the release of Ca2+. Similarly, GPR55-selective 
antagonists failed to inhibit LPI-induced increases in Ca2+ signal. This data therefore supports the 
theory that GPR55 activation and coupling to Gαq does not induce the release of Ca
2+ from 
intracellular stores in DU145 cells. This suggests that LPI is most likely mediating its effects 
through another unknown target in this prostate cancer cell line (Figure 4.1). 
91 
 
Due to time constraints, the role of GPR55 in inducing CREB phosphorylation in the DU145 cell 
line was not fully elucidated. The fact that nanomolar concentrations of SY-020 induced increases 
in nuclear pCREB fluorescence supports the proposal that GPR55 does mediate the induction of 
CREB phosphorylation in DU145 cells. This is consistent with the fact that CREB is directly 
involved in controlling the expression of genes that are essential for cancer cell proliferation and 
survival (Mitton et al., 2011). Ideally the next actions to take would be to identify if the GPR55 
antagonists tested in this study are capable of inhibiting the LPI- and SY-020-induced 
phosphorylation of CREB. Preliminary data indicates that 3-10 μM concentrations of both 
antagonists inhibit pCREB activation induced by 1 μM LPI (Penman, experimental work in 
progress). 
 
4.3. GPR55 cross-talk mechanisms 
Despite the recent emergence of selective pharmacological tools for GPR55, the selectivity of 
certain ligands for this orphan receptor is still contentious. For instance, Soga et al. (2005) suggested 
that LPI-induced cellular effects were mediated by the orphan receptor GPR119 in rat hepatoma 
cells overexpressing human GPR119. In contrast though, Piñeiro et al. (2011) found that 
knockdown of GPR119 in prostate and ovarian cancer cells did not alter LPI-induced cellular 
effects, which indicated that LPI was signalling via GPR55 instead. The data presented herein 
suggests that LPI does not induce Ca2+ release via GPR55 in the DU145 prostate cancer cell line 
because selective GPR55 antagonists failed to inhibit LPI-induced increases in Ca2+ signal. 
Similarly, a high concentration of LPI and SY-020 (10 µM) produced an increase in intracellular 
Ca2+ in control HEK293 cells which conflicts with previous data (Henstridge et al., 2009a). LPI at 
high concentrations could be signalling through another target in these native cell lines, perhaps 
GPR119. It is difficult to suggest which target LPI could be signalling through however. 
Evidence of GPR55 pharmacological communication with the orphan receptor GPR18 has 
emerged in recent years. Although LPI is not a putative agonist of the orphan receptor GPR18, it 
was capable of exerting minimal stimulation of microglial migration that was independent of 
concentration (McHugh et al., 2010). However, this microglial migration was more than likely 
induced via GPR55 because microglia also express GPR55 mRNA (Pietr et al., 2009). However, 
GPR18 is responsive to the agonists O-1602 (Ashton, 2012) and NAGly (Kohno et al., 2006) and 
both O-1602 (Schmuhl et al., 2014; Schuelert & McDougall, 2011) and NAGly (Penman, 2013) 
have been implicated in signalling via GPR55. This suggests that GPR18 may participate in cross-
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talk mechanisms with GPR55 or may cross-antagonise GPR55. For instance, Schicho et al. (2011) 
found that O-1602 reduced disease severity and inhibited neutrophil recruitment in a model of 
experimental colitis using a mechanism that was independent of GPR55, CB1 and CB2 receptors. 
This implicates an additional target of mediating these effects, most likely GPR18. It is worth 
noting that the putative GPR55 antagonist O-1918 (Schmuhl et al., 2014; Schuelert & McDougall, 
2011) is also thought to act as an antagonist at GPR18 (Caldwell et al., 2013), but this theory is 
controversial because it has recently been found that O-1918 induced an increase in MAPK activity 
and Ca2+ mobilisation in GPR18-HEK293 cells (Console-Bram et al., 2014). Interestingly, the CB1 
receptor agonists SR141716A and Δ9-THC induced biased effects at GPR55 and GPR18. 
SR141716A acted as an agonist at GPR55 and as a weak antagonist at GPR18, whereas Δ9-THC 
acted as a weak antagonist at GPR55 and as an agonist at GPR18 (Fuchs et al., 2013). This supports 
the idea of cross-antagonism occurring between these two receptors. In consideration of previous 
evidence, this could explain why a single GPR55 receptor antagonist would not be effective. 
Interfering with the communication between these two receptors, i.e. through the use of 
pharmacological tools or siRNA, could potentially be a more effective way to inhibit Ca2+ release 
from intracellular stores in native cell lines such as the DU145 prostate cancer cell line.  
GPR55 is also thought to participate in cross-talk mechanisms with cannabinoid receptors. Kargl 
et al. (2012) demonstrated that GPR55 formed heteromers with CB1 receptor upon agonist 
stimulation in GPR55/CB1-HEK293 cells. Both receptors were found to possess a modulatory 
effect on each other’s signalling pathways. Interestingly, although CB1 expression inhibited GPR55-
mediated transcription factor activation and ERK activation, the presence of GPR55 enhanced 
CB1-mediated ERK and NFAT activation in GPR55/CB1-HEK293 cells.  
 
There is increasing amounts of evidence supporting the existence of GPR55-CB2 cross-talk 
mechanisms (Irving, 2011). Moreno et al. (2014) demonstrated that CB2 receptor and GPR55 form 
heteromers in co-transfected GPR55/CB2-HEK293 cells and in breast and glioblastoma cancer 
cell lines. These findings are particularly intriguing in consideration of the results observed in the 
DU145 prostate cancer cells investigated herein. These GPR55/CB2 receptor heteromers displayed 
cross-talk and cross-antagonism at the level of cAMP and p-ERK pathways. The authors therefore 
suggested that GPR55/CB2 receptor heteromers drive biphasic signalling responses via cross-
antagonism (Moreno et al., 2014). In line with this, Balenga et al. (2014) demonstrated that GPR55 
and CB2 co-precipitated in the membrane extracts of HEK293 cells and co-localised and formed 
heteromers in HEK293 cells. Heterodimerisation of these receptors led to attenuation in GPR55-
mediated activation of transcription factors e.g. CRE, NFAT, but ERK-MAPK was increased in 
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the presence of CB2. Balenga et al. (2011) also observed that GPR55 expression occurred in 
neutrophils and GPR55 activation resulted in the recruitment of neutrophils to sites of injury. It 
was suggested that GPR55 synergised with CB2 receptors in order to recruit neutrophils and 
GPR55 would prevent the exacerbative inflammatory responses that would occur with CB2-
mediated recruitment alone. Schmuhl et al. (2014) observed that the CB2 receptor agonist CBD 
induced migration and p42/44 MAPK phosphorylation in mesenchymal stem cells. These effects 
were inhibited by AM-630 (CB₂ receptor antagonist) and O-1602 (GPR55 agonist). The authors 
theorised that upstream activation of CB2 receptor as well as inhibition of GPR55 were found to 
be involved in the activation of p42/44 MAPK which conferred downstream induction of 
migration.  
 
The potential cross-talk mechanisms described could explain for the contradictory evidence 
provided on GPR55 pharmacology to date. Perhaps GPR55 interaction with other receptors – 
GPR18, cannabinoid receptors or otherwise – may be responsible for the differential effects 
previously reported following GRP55 stimulation in different in vitro and in vivo systems. This could 
also aid in the understanding of the results presented in the current study, whereby GPR55 does 
not appear to be responsible for the induction of Ca2+ release in DU145 cancer cells and in control 
HEK293 cells. 
 
4.4. The role of GPR55 in neurodegeneration 
 
Cannabinoid receptors are expressed in the brain and peripheral nervous system (Cabral & 
Marciano-Cabral, 2005; Pertwee, 2005) and have long been associated with the regulation of CNS 
development and synaptic plasticity (Berghuis et al., 2007; Harkany et al., 2008; Mulder et al., 2008). 
GPR55 mRNA has also been identified in numerous regions of the brain e.g. frontal cortex, 
hypothalamus, striatum, amygdala and cerebellar granule cells (Chiba et al., 2011; Kerr et al., 2013; 
Ryberg et al., 2007; Sawzdargo et al., 1999) and GPR55 activity in the brain has been associated with 
a variety of functions. For instance, GPR55 was suggested to have a modulatory effect on 
neurotransmitter release from synapses in the brain. GPR55 agonists were found to cause a slow 
release of Ca2+ from intracellular stores, which enabled synaptic transmission to occur. This effect 
was not seen in GPR55-/- mice (Sylantyev et al., 2011, 2013). However, there is a growing amount 
of evidence focusing on GPR55 regulation of neuroimmune function. Apoptotic mechanisms have 
previously been associated with neurodegenerative conditions (Mattson, 2000). The induction of 
caspase-mediated apoptosis is thought to be implicated in neurodegeneration and aging (Bredesen, 
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2009; D’Amelio et al., 2011; Friedlander, 2003; Zhang et al., 2003) and cannabinoids e.g. Δ9-THC, 
2-AG and AEA, have been shown to induce neuroprotective effects in neurodegenerative models 
(Campbell, 2001; Downer et al., 2007; Gowran et al., 2011; Noonan et al., 2010). Preliminary findings 
presented in the current study showed that LPI attenuated the expression of caspase-3 in cortical 
neurons challenged with β-amyloid. This attenuation appeared to be somewhat reversed by the 
antagonist C390-0219, but not by D327-0013. This suggests that LPI signalling via GPR55 
promotes a protective effect on neurons that are undergoing Aβ-induced degeneration.  
 
Previous studies suggest that GPR55 has a regulatory function in models of neurodegeneration. 
Janefjord et al. (2013) employed the use of an in vitro model of AD and reported that the putative 
ligand for GPR55, O-1602, reduced the formation of aggregated β-amyloid fibrils and reduced 
activation of the microglial BV-2 cell line in response to lipopolysaccharide (LPS). When LPS-
conditioned media was removed from BV-2 cells and applied to neuronal cells, it was found that 
the application of O-1602 led to decreased neurotoxicity compared to control treatments where no 
agonists were applied. It is worth bearing in mind though that O-1602 is a putative agonist for both 
GPR55 and GPR18, as has been discussed previously. Janefjord et al. (2013) did not utilise any 
pharmacological tools or knockout models to elucidate through which receptor O-1602 was 
signalling. In contrast, Sisay et al. (2013) found that GPR55 knockout mice cross-bred onto the 
C57BL/6 background did not develop experimental autoimmune encephalomyelitis (EAE), the 
mouse model of Multiple Sclerosis (MS), as severely as their control counterparts. MS is an 
inflammatory autoimmune disease that is characterised by demyelination and chronic 
neurodegeneration (Perry et al., 2003). The findings presented by Sisay et al. (2013) therefore 
implicate GPR55 in potentiating neurodegenerative disease progression. Interestingly, 
C57BL/6.Cnr2tm1Dgen (CB2 receptor knockout) mice exhibited increased disease severity. This 
alludes to the possible GPR55-CB2 cross-talk mechanism that has been referred to previously. 
Perhaps GPR55 and CB2 cross-talk alters EAE disease progression. In consideration of the 
conflicting evidence provided on the regulatory role of GPR55 in neurodegenerative conditions, 
the results of the current study are therefore promising. The current data suggests that the selective 
GPR55 antagonist, C390-0219, has a somewhat attenuative effect on LPI-induced neuroprotection, 
thus implicating GPR55 in mediating a neuroprotective function. However, the findings made by 
Sisay et al. (2013) illustrate the importance of using other models such as siRNA or in vivo knockout 
models when seeking to delineate the (patho)physiological function of GPR55. 
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Future investigations to conduct should include treating Aβ-challenged cortical neurons with SY-
020 and observe if it has any neuroprotective effects, like it does with LPI. If positive effects are 
observed, tools to block GPR55 function e.g. selective antagonists, siRNA, knockout models,   
could then be applied to fully validate if GPR55 has a neuroprotective function in a model of AD. 
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Conclusion 
 
GPR55 is a putative cannabinoid receptor whose mRNA is widely expressed throughout the body, 
particularly in the brain and in certain types of tumour. To date it has been extremely difficult to 
validate the physiological and pathological roles of GPR55 due to an absence of selective 
pharmacological tools. However, with the recent development of selective antagonists and agonists 
for GPR55, the delineation of the pathophysiological functions of GPR55 may fast become a 
reality. 
 
In this study it was shown that two novel and selective antagonists, D327-0013 and C390-0219 (3 
μM), significantly inhibited the induction of Ca2+ release by LPI, the endogenous agonist for 
GPR55, in a HEK293 cell line that stably overexpresses GPR55 (hGPR55-HEK293). Similarly, 
D327-0013 (3 μM) significantly inhibited the GPR55-mediated Ca2+ release induced by a novel 
and selective GPR55 agonist, SY-020, in this cell line.  
 
The data presented herein is promising because it demonstrates the effectiveness of selective 
pharmacological tools for GPR55. The pharmacology of GPR55 has remained a controversial 
issue ever since its discovery and it is now becoming ever more apparent that GPR55 participates 
in cross-talk mechanisms with other receptors e.g. GPR18, cannabinoid receptors. In future it will 
therefore be crucial to use alternative methods to validate the selectivity of ligands for GPR55. For 
instance, siRNA should be applied in in vitro cells, such as the cell lines used in this study, to validate 
GPR55-mediated signalling pathways. The use of in vivo animal models e.g. GPR55 knockouts, 
would also aid in better understanding the physiological roles of this receptor. The data presented 
in the current study will serve to advance research into the physiological role of GPR55 and should 
contribute to the validation of GPR55 as a therapeutic target.  
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